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A B S T R A C T
Background
Kaposi’s sarcoma remains the most common cancer in Sub-Saharan Africa and the second most common cancer in HIV-infected
patients worldwide. Since the introduction of highly active antiretroviral therapy (HAART), there has been a decline in its incidence.
However, Kaposi’s sarcoma continues to be diagnosed in HIV-infected patients.
Objectives
To assess the added advantage of chemotherapy plusHAART compared toHAART alone; and the advantages of different chemotherapy
regimens in HAART and HAART naive HIV infected adults with severe or progressive Kaposi’s sarcoma.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and , GATEWAY, the WHO
Clinical Trials Registry Platform and the US National Institutes of Health’s ClinicalTrials.gov for ongoing trials and the Aegis archive
of HIV/AIDS for conference abstracts. An updated search was conducted in July 2014.
Selection criteria
Randomised trials and observational studies evaluating the effects of any chemotherapeutic regimen in combination with HAART
compared to HAART alone, chemotherapy versus HAART, and comparisons between different chemotherapy regimens.
Data collection and analysis
Two review authors assessed the studies independently and extracted outcome data. We used the risk ratio (RR) with a 95% confidence
interval (CI) as the measure of effect. We did not conduct meta-analysis as none of the included trials assessed identical chemotherapy
regimens.
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Main results
We included six randomised trials and three observational studies involving 792 HIV-infected adults with severe Kaposi’s sarcoma.
Seven studies included patients with a mix of mild to moderate (T0) and severe (T1) Kaposi’s sarcoma. However, this review was
restricted to the subset of participants with severe Kaposi’s sarcoma disease.
Studies comparing HAART plus chemotherapy toHAART alone showed the following: one trial comparing HAART plus doxorubicin,
bleomycin and vincristine (ABV) to HAART alone showed a significant reduction in disease progression in the HAART plus ABV
group (RR 0.10; 95% CI 0.01 to 0.75, 100 participants); there was no statistically significant reduction in mortality and no difference
in adverse events. A cohort study comparing liposomal anthracyclines plus HAART to HAART alone showed a non-statistically
significant reduction in Kaposi’s sarcoma immune reconstitution inflammatory syndrome in patients that received HAART plus
liposomal anthracyclines (RR 0.49; 95% CI 0.16 to 1.55, 129 participants).
Studies comparing HAART plus chemotherapy to HAART plus a different chemotherapy regimen showed the following: one trial
involving 49 participants and comparing paclitaxel versus pegylated liposomal doxorubicin in patients on HAART showed no dif-
ference in disease progression. Another trial involving 46 patients and comparing pegylated liposomal doxorubicin versus liposomal
daunorubicin showed no participants with progressive Kaposi’s sarcoma disease in either group.
Studies comparing different chemotherapy regimens in patients from the pre-HAART era showed the following: in the single RCT
comparing liposomal daunorubicin to ABV, there was no significant difference with the use of liposomal daunorubicin compared to
ABV in disease progression (RR 0.78; 95% CI 0.34 to 1.82, 227 participants) and overall response rate. Another trial involving 178
participants and comparing oral etoposide versus ABV demonstrated no difference in mortality in either group. A non-randomised trial
comparing bleomycin alone to ABV demonstrated a higher median survival time in the ABV group; there was also a non-statistically
significant reduction in adverse events and disease progression in the ABV group (RR 11; 95% CI 0.67 to 179.29, 24 participants).
An additional non-randomised study showed a non-statistically significant overall mortality benefit from liposomal doxorubicin as
compared to conservative management consisting of either bleomycin plus vinblastine, vincristine or single-agent antiretroviral therapy
alone (RR 0.93; 95% CI 0.75 to 1.15, 29 participants). The overall quality of evidence can be described as moderate quality. The
quality of evidence was downgraded due to the small size of many of the included studies and small number of events.
Authors’ conclusions
The findings from this review suggest that HAART plus chemotherapy may be beneficial in reducing disease progression compared
to HAART alone in patients with severe or progressive Kaposi’s sarcoma. For patients on HAART, when choosing from different
chemotherapy regimens, there was no observed difference between liposomal doxorubicin, liposomal daunorubicin and paclitaxel.
P L A I N L A N G U A G E S U M M A R Y
Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Kaposi’s sarcoma was the first tumor to be described in association with HIV infection and is an AIDS-defining condition. It is also
known as Kaposi’s sarcoma-associated herpes virus (KSHV) as Herpes virus 8 (HHV8) is recognized as an essential and necessary factor
in the pathogenesis of KS. Nonetheless, not all HHV-8-infected individuals will develop the disease. The abnormal cells of KS form
purple, red, or brown patches, plaques or tumors on the skin. There is no universally accepted system for staging Kaposi’s sarcoma.
The most commonly used staging system for AIDS-related KS in adults is the AIDS Clinical Trial Group (ACTG) staging.
This review evaluated the effects of highly active antiretroviral therapy (HAART) and chemotherapy, or different chemotherapy regimens
for severe or progressive Kaposi’s sarcoma in HIV infected adults.
We found six randomised controlled trials and three observational studies that assessed the effects of HAART plus chemotherapy
compared with HAART alone; HAART plus chemotherapy compared with HAART plus another chemotherapy regimen; and chemo-
therapy compared with chemotherapy in the time before HAART was available. Of the nine included studies, seven included patients
with a mix of mild to moderate (T0) Kaposi’s sarcoma and severe (T1) Kaposi’s sarcoma. There was no universal definition for what
severity of disease was considered chemotherapy-requiring. For this review, we only extracted data for 792 HIV infected adults with
severe Kaposi’s sarcoma disease.
The findings from this review suggest that HAART plus chemotherapy may be beneficial in reducing disease progression compared
to HAART alone in patients with severe or progressive Kaposi’s sarcoma. For patients on HAART, in choosing among different
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chemotherapy regimens, there was no observed difference between liposomal doxorubcin, liposomal daunorubicin, and paclitaxel. The
overall quality of evidence in this review can be described as moderate.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
HAART + ABV compared to HAART alone for the treatment of severe Kaposi’s sarcoma in HIV- infected adults (Mosam 2012) - RCT
Patient or population: HIV-infected adults with severe (T1) Kaposi’s sarcoma
Settings: Durban, South Af rica
Intervention: HAART + ABV
Comparison: HAART alone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
HAART alone HAART + ABV
M ortality 240 per 1000 221 per 1000
(108 to 451)
RR 0.92
(0.45 to 1.88)
100
(1 study)
⊕⊕⊕©
moderate1
Progressive disease 200 per 1000 20 per 1000
(2 to 150)
RR 0.1
(0.01 to 0.75)
100
(1 study)
⊕⊕⊕©
moderate1
Clinical response -
complete response
80 per 1000 160 per 1000
(51 to 498)
RR 2
(0.64 to 6.22)
100
(1 study)
⊕⊕⊕©
moderate1
Clinical response - par-
tial response
280 per 1000 479 per 1000
(283 to 815)
RR 1.71
(1.01 to 2.91)
100
(1 study)
⊕⊕⊕©
moderate1
Clinical response - sta-
ble disease
160 per 1000 10 per 1000
(0 to 158)
RR 0.06
(0 to 0.99)
100
(1 study)
⊕⊕⊕©
moderate1
Clinical response -
overall response (com-
plete and partial)
360 per 1000 641 per 1000
(418 to 979)
RR 1.78
(1.16 to 2.72)
100
(1 study)
⊕⊕⊕©
moderate1
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Adverse events
Follow-up: mean 12
months
520 per 1000 458 per 1000
(307 to 686)
RR 0.88
(0.59 to 1.32)
100
(1 study)
⊕⊕⊕©
moderate1
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
ABV: doxorubicin, bleomycin and vincrist ine; CI: conf idence interval; HAART: highly act ive ant iretroviral therapy; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1There were very few events with very wide conf idence intervals.
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B A C K G R O U N D
Acquired immunodeficiency syndrome (AIDS)-defining cancers,
including Kaposi’s sarcoma, have become common comorbidities
afflicting HIV-infected individuals (Casper 2011). Kaposi’s sar-
coma was the first tumour to be described in association with
HIV infection and is an AIDS-defining condition. Kaposi’s sar-
coma remains the most common HIV-associated cancer in Sub-
Saharan Africa and the second most common cancer in HIV-in-
fected patients worldwide (Gantt 2010). Since the introduction
of ’highly active antiretroviral therapy’ (HAART) or combination
antiretroviral therapy (cART), there has been a rapid decline in
the incidence of Kaposi’s sarcoma, especially in Western countries
where HAART is readily available (Di Lorenzo 2007; Jones 2000;
Mocroft 2004). The reduction in incidence of Kaposi’s sarcoma
is less clear in resource poor settings (Semeere 2012). However, it
continues to be diagnosed in HIV-infected patients, even among
patients with effective viral load suppression and high CD4 counts
(Khanlou 2000; Maurer 2007). Survival after a diagnosis of KS in
the modern HAART era continues to be sub-optimal in resource
poor settings (Freeman 2013). Together, incident cases and poor
survival in some settings emphasises the importance of under-
standing the treatment options for severe or progressive Kaposi’s
sarcoma.
Description of the condition
Kaposi’s sarcoma is thought to originate from herpes virus 8
(HHV8)-infected lymphatic endothelial cells and is also known
as Kaposi’s sarcoma-associated herpes virus (KSHV). HHV8 is
recognised as an essential and necessary factor in the pathogenesis
of Kaposi’s sarcoma (Browning 1994; Chang 1994; Davis 1997).
Nonetheless, not all HHV-8-infected individuals will develop the
disease.
Kaposi’s sarcoma lesions are comprised of both distinctive spindle
cells that line lymph or blood vessels and a variable inflamma-
tory infiltrate, suggesting that it may result from reactive hyper-
proliferation induced by chronic inflammation and is not a true
neoplasm (Martellotta 2009).The abnormal cells of Kaposi’s sar-
coma form purple or brown patches, plaques or tumours on the
skin. Biopsy for definitive diagnosis is recommended to distin-
guish Kaposi’s sarcoma from other skin conditions that can look
similar, which may include bacillary angiomatosis, non-Hodgkin
lymphoma, and cutaneous fungal or bacterial infections (Krown
2006).
There is no universally accepted system for staging AIDS-related
Kaposi’s sarcoma. The most commonly used staging system for
AIDS-related Kaposi’s sarcoma in adults was developed by the
AIDS Clinical Trial Group (ACTG) of the National Institutes of
Health (Krown 1989). It is important to note that this staging
system is most frequently used in research. Clinically, patients may
be groupedmore generally by a clinician into either a) sick patients
needing an immediate fast-acting intervention (clinically severe
Kaposi’s sarcoma) or b) those patients that can be treated with
HAART alone (clinically mild to moderate Kaposi’s sarcoma).
There is continued debate in the literature as to the definition
of the severity of KS that is truly requiring of immediate fast-
acting intervention as compared to HAART alone, and different
definitions have been used in different studies (Martin 2013).
In ACTG staging, patients are categorised according to three pa-
rameters.
• Extent of tumour (T): a favourable prognosis (T0) is
associated with disease limited to the skin or with minimal
involvement of the oral cavity. Those with associated
lymphoedema, more extensive oral cavity involvement or other
visceral disease are considered to have a poor prognosis (T1).
• Immune status (I): the degree of immunosuppression from
the HIV infection is an important prognostic factor. Patients
with a CD4 count greater than 200 cells/µl are considered to
have a favourable prognosis (I0), while those with a lower CD4
count are classified as having a poor prognosis (I1).
• Severity of systemic illness (S): features associated with a
poor risk included the following (S1): a history of opportunistic
infection, thrush, B symptoms (fever, night sweats, significant
weight loss, diarrhoea for more than two weeks). Patients without
any of these factors have a more favourable prognosis (S0).
Description of the intervention
HAART has been a very important step in the treatment of
AIDS-related Kaposi’s sarcoma and has led to a substantial re-
duction in morbidity and mortality (Bower 2006; Carrieri 2003;
Di Lorenzo 2007; Engels 2006; Grulich 2001). In addition to
HAART,many other potential systemic and local therapeutic regi-
mens exist, which have been studied in HIV-infected adults. Gen-
erally, more widespread disease, or disease affecting internal or-
gans, is treated with systemic therapy (including interferon alpha,
liposomal anthracyclines or paclitaxel). Liposomal anthracyclines
were found in the previous version of this Cochrane review to have
a superior response rate without an increase in toxic side effects
(Dedicoat 2003), and have been adopted bymany as first-line ther-
apy for severe Kaposi’s sarcoma (Di Trolio 2006). However, at this
time there are no guidelines from the World Health Organization
regarding liposomal anthracyclines as first-line therapy and access
to these drugs is still very limited in the developing world. Since
the prior Cochrane review, more studies have been published in
this area, necessitating an update of the literature.With the advent
of ART, local treatment is often reserved for patients who do not
respond to systemictherapy.
Why it is important to do this review
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The incidence of AIDS-related Kaposi’s sarcoma remains high in
many countries where HIV-1 is prevalent, especially in Sub-Sa-
haran Africa. This review aims to identify high-quality studies of
therapy for clinically severe or treatment-refractory Kaposi’s sar-
coma. Studies using HAART plus chemotherapy or different che-
motherapy regimens in both the pre- andpost-HAART era will
be included. The previous version of this review included HIV-
1-infected adult patients with both mild and severe/progressive
Kaposi’s sarcoma (Dedicoat 2003). However, this update of the
review will be restricted to severe or progressive Kaposi’s sarcoma.
Another ongoing Cochrane systematic review will address treat-
ment for mild and moderate Kaposi’s sarcoma in ART-naive HIV-
infected individuals. We aim to present the best available evidence
from randomised controlled trials and observational studies. The
findings from our review will help to guide policy and practice
on the treatment of AIDS-related Kaposi’s sarcoma in adults with
HIV infection.
O B J E C T I V E S
Toassess the added advantage of chemotherapy plusHAARTcom-
pared to HAART alone; and the advantages of different chemo-
therapy regimens in HAART and HAART naive HIV infected
adults with severe or progressive Kaposi’s sarcoma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials and observational studies with a
comparison group.
Types of participants
HIV-infected adults diagnosed with Kaposi’s sarcoma, considered
to have the following.
• Severe Kaposi’s sarcoma, requiring anti-Kaposi’s sarcoma
therapy, defined as patients with:
◦ ACTG T1 disease; or
◦ where ACTG staging is not available or analysis by
ACTG stage is unobtainable, defined as:
⋄ documented or clinically suspected pulmonary or
gastrointestinal Kaposi’s sarcoma;
⋄ oral Kaposi’s sarcoma that interferes with
chewing or swallowing;
⋄ Kaposi’s sarcoma tumour-associated oedema that
affects function;
⋄ tumour ulceration that is unresponsive to general
local care;
⋄ life-threatening Kaposi’s sarcoma, deemed by the
study authors to require immediate anti-Kaposi’s sarcoma
therapy such as chemotherapy.
• Progressive disease despite prior treatment. Progression is
defined according to ACTG response criteria (Krown 1989) as:
◦ an increase of 25% or more in the size of previously
existing lesions;
◦ the appearance of new lesions or new sites of disease;
◦ a change in the character of 25% or more of the skin
or oral lesions from macular to plaque-like or nodular;
◦ the development of new or increasing tumor-
associated edema or effusions also considered to represent disease
progression.
Types of interventions
Any chemotherapeutic regimen in combination with HAART
compared to HAART alone, chemotherapy versus HAART, and
comparisons between chemotherapy regimens both the pre-
HAART era and while on HAART. For this review, HAART is
defined as a combination of three or more antiretroviral agents, ei-
ther taken individually or in fixed-dose combinations, as opposed
to single or dual-drug therapy.
Types of outcome measures
Primary outcomes
• Mortality
• Progression of Kaposi’s sarcoma
• Clinical response (complete, partial and no response),
which includes assessment of the number of lesions, size and
oedema (Krown 1989)
Secondary outcomes
• Time to response
• Adverse events (including toxicity, worsening of co-existent
disease or both)
• Kaposi’s sarcoma immune reconstitution inflammatory
syndrome (IRIS)
• Adherence
• Quality of life
Search methods for identification of studies
Electronic searches
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We formulated a comprehensive and exhaustive search strategy in
order to identify all relevant studies regardless of language or pub-
lication status (published, unpublished, in press and in progress)
(Table 1; Table 2; Table 3). Full details of the Cochrane HIV/
AIDS Review Group methods and the journals handsearched are
published in the section on Collaborative Review Groups in The
Cochrane Library (Cochrane HIV/AIDS Group 2011).
We searched the Cochrane CENTRAL andMEDLINE databases
on November 9, 2012 (1980 to 2012); EMBASE and GATEWAY
on November 26, 2012 (1980 to 2014). An updated search of the
databases was done on July 4, 2014.
• Cochrane Central Register of Controlled Trials
(CENTRAL) 2012 (Issue 10);
• MEDLINE;
• EMBASE;
• GATEWAY.
Along with MeSH terms and relevant keywords, we used the
Cochrane highly sensitive search strategy for identifying reports
of randomised controlled trials in MEDLINE and the Cochrane
HIV/AIDSGroup’s existing validated strategies for identifying ref-
erences relevant to HIV infection and AIDS. The search strategy
was iterative, in that we searched the references of included studies
for additional relevant references. There was no language restric-
tion.
We also searched for unpublished and ongoing trials using relevant
search terms in:
• the US National Institutes of Health’s Clinical Trials.gov (
www.clinicaltrials.gov); and
• the WHO Clinical Trials Registry Platform (ICTRP).
Searching other resources
We searched the Aegis archive of HIV/AIDS conference abstracts
(http://www.aegis.org/) on 24 May 2013. Aegis includes abstracts
for the following conferences:
• International AIDS Society, International AIDS
Conference (IAC), 1985 to 2006;
• Conference on Retroviruses and Opportunistic Infections
(CROI), 1994 to 2008;
• European AIDS Society Conference, 2001 and 2003;
• International AIDS Society, Conference on HIV
Pathogenesis, Treatment and Prevention (IAS), 2001 to 2005;
• British HIV/AIDS Association, 2001 to 2010;
• US National HIV Prevention Conference, 1999, 2001,
2003, 2005 2007, 2009 and 2011.
We also searched the CROI and International AIDS Society web-
sites for abstracts presented at conferences subsequent to those
listed above (CROI, 2009 to 2012; IAC, 2008 to 2010; IAS, 2007
to 2011). In addition, we contacted experts in the field to identify
further potentially eligible studies.
Data collection and analysis
Selection of studies
Two authors (GO and CO) independently read the titles and ab-
stracts from the search output to identify potentially eligible stud-
ies. We obtained full-text articles for all citations identified as po-
tentially eligible and two authors independently inspected these to
establish the relevance of the article using the prespecified criteria.
We resolved all disagreements by discussion and by contacting the
third author (EF).
Data extraction and management
We designed a standardised data extraction form and two authors
independently extracted data onto this.We extracted the following
characteristics from each included study:
• Administrative details: author(s); published or unpublished;
year of publication; year(s) in which study was conducted.
• Details of the study: study design; type, duration and
completeness of follow-up; study location.
• Details of participants: age; gender; clinical characteristics
(e.g. baseline CD4 cell count, viral load, opportunistic
infections).
• Details of treatment.
• Details of outcomes.
• Details necessary for ’Risk of bias’ assessment.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of each
study using the ’Risk of bias’ assessment tool described in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011).We resolved any disagreement by discussion.TheCochrane
approach assesses risk of bias in individual studies across six do-
mains: sequence generation, allocation concealment, blinding, in-
complete outcome data, selective outcome reporting and other
potential biases.
Sequence generation (checking for selection bias)
• Adequate: investigators described a random component in
the sequence generation process, such as the use of random
number table, coin tossing, card or envelope shuffling.
• Inadequate: investigators described a non-random
component in the sequence generation process, such as the use of
odd or even date of birth, algorithm based on the day or date of
birth, hospital or clinic record number.
• Unclear: insufficient information to permit judgement of
the sequence generation process.
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Allocation concealment (checking for selection bias)
• Adequate: participants and the investigators enrolling
participants cannot foresee assignment (e.g. central allocation or
sequentially numbered, opaque, sealed envelopes).
• Inadequate: participants and investigators enrolling
participants can foresee upcoming assignment (e.g. an open
random allocation schedule, a list of random numbers), or
envelopes were unsealed, non-opaque or not sequentially
numbered.
• Unclear: insufficient information to permit judgement of
the allocation concealment or the method is not described.
Blinding (checking for performance bias and detection bias)
• Adequate: blinding of the participants, key study personnel
and outcome assessor and it is unlikely that the blinding could
have been broken. Not blinded but a situation where non-
blinding is unlikely to introduce bias.
• Inadequate: no blinding or incomplete blinding when the
outcome is likely to be influenced by lack of blinding.
• Unclear: insufficient information to permit judgement of
the adequacy or otherwise of the blinding.
Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
• Adequate: no missing outcome data, reasons for missing
outcome data are unlikely to be related to true outcome or
missing outcome data are balanced in numbers across groups.
• Inadequate: reasons for missing outcome data are likely to
be related to true outcome, with either imbalance in numbers
across groups or reasons for missing data.
• Unclear: insufficient reporting of attrition or exclusions.
Selective reporting
• Adequate: a protocol is available and clearly states that the
primary outcome is the same as in the final trial report.
• Inadequate: the primary outcome differs between the
protocol and final trial report.
• Unclear: no trial protocol is available or there is insufficient
reporting to determine whether selective reporting is present.
Other sources of bias
• Adequate: there is no evidence of bias from other sources.
• Inadequate: there is potential bias present from other
sources (e.g. early stopping of trial, fraudulent activity, extreme
baseline imbalance or bias related to specific study design).
• Unclear: insufficient information to permit judgement of
other forms of bias.
For non-randomised studies, we used the Newcastle-Ottawa Scale
to assess the risk of bias in three major areas: selection of study
groups, comparability of groups and ascertainment of outcomes
(Appendix 1).
Measures of treatment effect
For randomised controlled trials and observational studies, we cal-
culated the risk ratio (RR) for dichotomous outcomes with a 95%
confidence interval (CI). For continuous data we calculated the
mean difference with a 95% CI.
Dealing with missing data
We did not impute missing data. We contacted the authors of the
included studies if there were any missing or unclear data.
Assessment of heterogeneity
We planned to assess statistical heterogeneity by visually inspect-
ing the forest plots to detect overlapping CIs, applying the Chi
2 test (P value < 0.10 considered statistically significant) and by
using the I2 statistic, where an I2 value of greater than 75% repre-
sents substantial heterogeneity. The studies differed significantly
in terms of participants and interventions, precluding any meta-
analysis.
Assessment of reporting biases
We did not explore the likelihood of reporting bias using funnel
plots, since we did not combine any of the studies in a meta-anal-
ysis. However, we conducted a comprehensive search to identify
all relevant studies.
Data synthesis
Wehave presented the results of individual studies narratively since
meta-analysis was not possible.
Quality of evidence
We assessed the quality of evidence across each outcome measure
using the GRADE approach. The quality rating across studies has
four levels: high, moderate, low or very low. Randomised trials
are categorised as high quality but can be downgraded; similarly,
observational studies are categorised as low quality and can be
downgraded or upgraded. We used the GRADEpro software to
generate GRADE evidence profiles and ’Summary of findings’
tables.
Subgroup analysis and investigation of heterogeneity
We planned to explore heterogeneity by subgroup analyses. How-
ever, we did not combine any of the studies in a meta-analysis.
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R E S U L T S
Description of studies
Results of the search
See the PRISMA flow diagram (Figure 1) and the Characteristics
of included studies table for details.
Figure 1. Study flow diagram
We conducted a search for studies in the various databases listed
in Search methods for identification of studies in May 2013 and
an updated search in July 2014. We obtained a total of 3615
titles and abstracts after de-duplication of references. Two authors
independently scanned through the titles and abstracts using our
prespecified inclusion criteria.We identified 65 potentially eligible
studies andobtained the full-text articles.Nine studies thatmet our
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inclusion criteria were included.We gave reasons for excluding any
potentially eligible study. See Characteristics of excluded studies.
Included studies
Types of studies
We included six randomised controlled trials (Cianfrocca 2010;
Cooley 2007; Gill 1996; Martin-Carbonero 2004; Mosam 2012;
Olweny 2005) and three observational studies (Bower 2009;
Grünaug 1998; Hernandez 1997). Where multiple papers were
published on the same cohort of patients, we refer to the pri-
mary study only, but refer to additional publications in the
Characteristics of included studies.
Types of participants
Of the nine included studies, seven had participants with a mix
of T0 and T1 Kaposi’s sarcoma (Bower 2009; Cianfrocca 2010;
Cooley 2007; Hernandez 1997; Martin-Carbonero 2004;Mosam
2012; Olweny 2005). Two studies had only T1 disease patients
(Gill 1996; Grünaug 1998). For all studies, we extracted data only
for participants meeting criteria of severe disease, as defined above.
All included studies did measure ACTG stage, and ultimately were
able to provide results according to stage after communicationwith
study authors. Therefore, for all included papers, only patients
withT1diseasewere included.Of note, the two studies included in
the prior Cochrane review on Kaposi’s sarcoma were not included
in the current review due to a mix of Kaposi’s sarcoma stages; T1
disease patients could not be separated from T0 (Northfelt 1998;
Stewart 1998).
Participants in all the studies were HIV-infected adults with
biopsy-proven Kaposi’s sarcoma. Mosam 2012 included 100 pa-
tients with T1 Kaposi’s sarcoma (out of a total of 112 treatment-
naive HIV-infected patients). It should be noted that T1 patients
in this study were deemed by the author not to require “urgent”
chemotherapy. Cianfrocca 2010 included 49 patients with T1 Ka-
posi’s sarcoma out of a total of 73 patients aged 18 years and
above. Bower 2009 included 254 patients of which 79 were T1
Kaposi’s sarcoma patients (Letang 2013 included a later version of
Bower’s UK cohort of 129 T1 Kaposi’s sarcoma patients). Cooley
2007 included 46 patients with T1 disease out of a total of 79
patients. Olweny 2005 included a total of 470 antiretroviral ther-
apy (ART)-naive patients, of which 376 had T1 Kaposi’s sarcoma.
Martin-Carbonero 2004 included 10 patients with T1 disease out
of a total of 28 HIV-infected patients with moderate to advanced
Kaposi’s sarcoma. Grünaug 1998 included 29 HIV-infected males
with pulmonary (T1)Kaposi’s sarcoma.Hernandez 1997 included
34 T1 Kaposi’s sarcoma patients out of a total of 44 homosexual or
bisexual men. Gill 1996 included 227 HIV-infected adults with
T1 disease. All participants met this review’s criteria of having se-
vere KS.
Types of interventions
None of the included studies with the same study design compared
similar interventions.
Mosam 2012 compared HAART plus doxorubicin, bleomycin
and vincristine (ABV) versus HAART alone. There were a total
of 100 T1 Kaposi’s sarcoma patients, with 50 in the HAART plus
ABV group and 50 in the HAART alone group. Chemotherapy
was started within one month of initiation of HAART. Of note,
when ABV was not available, oral etoposide was substituted.
Martin-Carbonero 2004 compared HAART plus pegylated lipo-
somal doxorubicin (PLD) versus HAART alone. There were a to-
tal of 10 T1 Kaposi’s sarcoma patients, with five in the HAART
plus PLD group and five in the HAART alone group. HAART
and chemotherapy were started simultaneously at the beginning
of the study.
The Bower 2009 (Letang 2013, Bower 2014) UK cohort included
patients on HAART alone as well as patients on HAART plus
liposomal anthracycline. Of the 79 T1 patients in the study, there
were a total of 73 patients with severe Kaposi’s sarcoma in the
HAART alone and HAART plus chemotherapy groups. Letang
2013, a pooled analysis of four cohort studies, included patients
from the Bower 2009 UK cohort. There were 129 T1 disease
patients out of a total of 213 patients, with 65 T1 patients in the
HAART plus liposomal anthracycline group and 64 T1 patients
in the HAART alone group. All T1 Kaposi’s sarcoma patients in
this study were meant to receive chemotherapy as per protocol;
patients who received HAART alone were therefore exceptions.
The original Bower 2009 cohort was not designed with the intent
to compare these two groups.
Cianfrocca 2010 compared HAART plus paclitaxel versus
HAART plus PLD. There were a total of 24 participants in the
paclitaxel group and 25 in the PLD group. Participants were re-
quired to receive HAART for at least 14 days before study enrol-
ment.
Cooley 2007 compared HAART plus pegylated liposomal dox-
orubicin versus HAART plus liposomal daunorubicin. Only 76
out of 80 patients in the overall study were on ART. There were a
total of 46 T1Kaposi’s sarcoma patients with 34 in the PLD group
and 12 in the liposomal daunorubicin group. The time interval
between commencement of HAART and chemotherapy, and the
type of HAART regimen received were not described.
Gill 1996 compared liposomal daunorubicin versus ABV in the
pre-HAART era. There were a total of 227 participants, with 116
in the liposomal daunorubicin group and 111 in the ABV group.
Olweny 2005was a four-arm trial that compared supportive care
versus supportive care plus oral etoposide, ABV and radiotherapy.
There were a total of 378ART-naive T1Kaposi’s sarcoma patients,
of which 178 were in the oral etoposide (90 patients) and ABV
(88 patients) groups.
There were four intervention groups in Hernandez 1997: alpha-2
interferon, ABV, bleomycin and ano treatment group.Tenpatients
with limited Kaposi’s sarcoma received alpha-2 interferon plus
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zidovudine, 24 patients with advanced Kaposi’s sarcoma (12 in
each group) received either intramuscular bleomycin or low-dose
ABV, and 10 “poor risk” patients received no treatment due to
financial constraint.
In Grünaug 1998, also performed in the pre-HAART era, 17 out
of the 20 participants in the liposomal doxorubicin group received
antiretroviral therapy. In the group that received conservativeman-
agement, 4 out of the 9 participants had bleomycin and vinblas-
tine or vincristine; five had no chemotherapy, and 2 of the 5 par-
ticipants that did not receive chemotherapy had interferon alpha.
Types of outcome measures
The outcomes reported were mortality (Bower 2009; Cooley
2007; Grünaug 1998; Hernandez 1997; Mosam 2012; Olweny
2005), Kaposi’s sarcoma immune reconstitution inflammatory
syndrome (IRIS) (Bower 2009), tumour response (Cianfrocca
2010; Cooley 2007; Gill 1996; Hernandez 1997; Martin-
Carbonero 2004; Mosam 2012; Olweny 2005), adverse events
(Cianfrocca 2010; Cooley 2007; Gill 1996; Grünaug 1998;
Hernandez 1997; Mosam 2012; Olweny 2005), time to re-
sponse (Cooley 2007;Gill 1996;Grünaug 1998;Hernandez 1997;
Olweny 2005) and quality of life (Cianfrocca 2010; Gill 1996;
Olweny 2005). However, Cianfrocca and Olweny did not report
quality of life according to disease stage. None of the included
studies reported outcome data on adherence.
Settings
The studies were conducted in various settings including: Ger-
many (Grünaug 1998), South Africa (Mosam 2012), Spain
(Martin-Carbonero 2004), the UK (Bower 2009), the USA (
Cianfrocca 2010; Cooley 2007;Gill 1996), Venezuela (Hernandez
1997) and Zimbabwe (Olweny 2005).
Risk of bias in included studies
For assessment results, please see the ’Risk of bias’ graph and sum-
mary (Figure 2; Figure 3), and the Newcastle-Ottawa quality as-
sessment scale for included cohort studies (Appendix 2). The over-
all methodological quality of the studies was acceptable. We ob-
tained additional information by contacting the study authors to
be able to make informed assessments where necessary.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We did not find information on the method of sequence gen-
eration and allocation concealment in any of the studies except
Olweny 2005.
Blinding
There was no blinding to intervention in any of the studies. How-
ever, the reported outcomes were objective and not likely to be
affected by lack of blinding. In the Cooley 2007 trial, an indepen-
dent AIDS expert without knowledge of the patient evaluated the
outcome.
Incomplete outcome data
There was no differential loss to follow-up in any of the studies.
Selective reporting
We did not find any evidence of selective outcome reporting in
any of the studies.
Other potential sources of bias
The Cianfrocca 2010 trial was terminated prematurely due to
slow accrual. There were some reported baseline imbalances in the
Martin-Carbonero 2004 and Mosam 2012 studies. The Mosam
2012 study patientswithT1diseasewere deemednot to “urgently”
require chemotherapy, and therefore may have been less sick than
the T1 patients in other studies included in this review. All T1 KS
patients in Bower 2009 were meant to receive chemotherapy as
per protocol, patients who received HAART alone were therefore
exceptions. We did not explore the potential for publication bias
since we did not combine any of the studies in a meta-analysis.
However, we conducted a comprehensive search to identify all
relevant studies.
For non-randomised studies: (Grünaug 1998) had a cohort
that was representative of HIV-infected adults with Kaposi’s sar-
coma and adjusted for potential confounders. Bower 2009 and
Hernandez 1997 did not report adjusting for any other poten-
tial confounders for all outcomes of interest. All included obser-
vational studies described complete follow up of the study par-
ticipants or characteristics of the participants lost to follow up
(Appendix 2).
Effects of interventions
See: Summary of findings for the main comparison HAART
+ ABV compared to HAART alone for the treatment of severe
Kaposi’s sarcoma in HIV-infected adults; Summary of findings
2 HAART + pegylated liposomal doxorubicin compared to
HAART alone for the treatment of severe Kaposi’s sarcoma
in HIV-infected adults; Summary of findings 3 HAART +
liposomal anthracycline compared to HAART alone for the
treatment of severe Kaposi’s sarcoma in HIV-infected adults;
Summary of findings 4 HAART + paclitaxel compared to
HAART + pegylated liposomal doxorubicin for the treatment
of severe Kaposi’s sarcoma in HIV-infected adults; Summary of
findings 5HAART + pegylated liposomal doxorubicin compared
to HAART + liposomal daunorubicin for the treatment of severe
Kaposi’s sarcoma in HIV-infected adults; Summary of findings
6 Liposomal daunorubicin compared to ABV for the treatment
of severe Kaposi’s sarcoma in HIV-infected adults; Summary of
findings 7 Oral etoposide compared to ABV for the treatment
of severe Kaposi’s sarcoma in HIV-infected adults; Summary of
findings 8Bleomycin compared toABV for the treatment of severe
Kaposi’s sarcoma in HIV-infected adults; Summary of findings
9 Liposomal doxorubicin compared to conservative management
for the treatment of severeKaposi’s sarcoma inHIV-infected adults
Highly active antiretroviral therapy (HAART) plus
chemotherapy versus HAART alone
Randomised controlled trials
HAART plus doxorubicin, bleomycin and vincristine (ABV)
versus HAART alone
InMosam 2012, in theHAART plus ABV group, ABVwas started
within one month of initiation of HAART. Of note, when ABV
was not available, oral Etoposide was given. This alternative che-
motherapy regimen was used in 31% of patients that received che-
motherapy overall.
The HAART regimen consisted of a fixed-dose combination of
stavudine (40 mg), lamivudine (150 mg) and nevirapine 200 mg.
The outcomes reported were:
Mortality
In the T1 Kaposi’s sarcoma group, there were a total of 11 deaths
out of 50 participants in the HAART plus ABV group compared
to 12 deaths out of 50 in the HAART alone group (RR 0.92; 95%
CI 0.45 to 1.88) (Analysis 1.1).
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Progression of Kaposi’s sarcoma
One out of 50 participants had progressive disease in the HAART
plus ABV group, compared to 10 participants out of 50 with
progressive disease in the HAART alone group(RR 0.10; 95% CI
0.01 to 0.75) (Analysis 1.2).
Clinical response (includes complete, partial and no response)
• Complete response
Eight out of 50 participants had a complete response in the
HAART plus ABV group, compared to four participants out of
50 with complete response in the HAART alone group(RR 2.0;
95% CI 0.64 to 6.22) (Analysis 1.3).
• Partial response
Twenty-four participants in the HAART plus ABV group had a
partial response compared to 14 participants in the HAART alone
group(RR 1.71; 95% CI 1.01 to 2.91).
• The overall response rate (complete and partial) in the
HAART plus ABV group was 32 out of 50 participants
compared to 18 in the HAART alone group(RR 1.78; 95% CI
1.16 to 2.72).
• Stable disease (no response)
There were no participants with stable disease in the HAART plus
ABV group and eight participants in theHAART alone group had
stable disease.
Adverse events
Twenty-three participants in the HAART plus ABV group and
26 in the HAART alone group had grade 3 to 5 adverse events
(includingKaposi’s sarcoma immune reconstitution inflammatory
syndrome (IRIS): four in the HAART plus ABV group and one
patient in the HAART alone group (RR 0.88; 95% CI 0.59 to
1.32) (Analysis 1.4).
HAART plus pegylated liposomal doxorubicin (PLD) versus
HAART alone
Martin-Carbonero 2004 included both T1 and T0 Kaposi’s sar-
coma patients. We present results only for participants with T1
Kaposi’s sarcoma. HAART and chemotherapy were started simul-
taneously at the beginning of the study (there were two antiretro-
viral therapy (HAART) treatment-naive patients). The HAART
regimen was protease inhibitor (PI) based, non-nucleoside reverse
transcriptase (NNRTI) based or PI plus NNRTI.
The outcomes reported were:
Clinical response (includes complete, partial and no response)
There were a total of 10 T1 Kaposi’s sarcoma patients, with five in
theHAART plus PLD group and five in the HAART alone group.
The authors combined the results for both partial and complete
response. In the HAART plus PLD group, four participants had a
complete/partial response, while none responded in the HAART
alone group. PLD plus HAART appeared to increase the rate of
both partial and complete response compared to HAART alone.
However, this difference was not statistically significant (risk ratio
(RR) 9; 95% confidence interval (CI) 0.61 to 133.08) (Analysis
2.1).
Prospective cohort study
HAART plus liposomal anthracycline versus HAART alone
In Bower 2009 (including Bower 2014 and Letang 2013), there
were 163 participants in the HAART alone group (131 were an-
tiretroviral-naive and 32were onHAARTat the time of diagnosis),
of which five participants had T1 disease. There were 73 patients
in the HAART plus liposomal anthracycline group, of which 68
had T1 Kaposi’s sarcoma. This study was not designed to compare
different treatment regimens for patients with T1 disease. Specif-
ically, the clinic followed guidelines that all T1 patients should be
treated with HAART plus liposomal anthracyclines, therefore T1
patients who were treated with HAART alone were particular ex-
ceptions. Outcome data were not presented according to Kaposi’s
sarcoma staging. Updated data from the same cohort were simi-
larly presented in Bower 2014. Letang 2013 included Bower’s UK
cohort of 213 patients, of which 129 had T1 Kaposi’s sarcoma,
with 65 patients in the HAART plus chemotherapy group and 64
in theHAART alone group. In order to ascertain outcome specific
to stage, the data reported below were provided after communica-
tion with the author of Letang 2013, and represent unpublished
Letang 2013 data.
The outcomes reported were:
Mortality/overall 12-month survival
A total of five out of 65 T1 participants in the HAART plus lipo-
somal anthracycline group died at the end of 12months compared
to four out of 64 participants in the HAART alone group (RR
1.23; 95% CI 0.35 to 4.38) (Analysis 3.1).
Kaposi’s sarcoma IRIS
Four out of 65 T1 participants in the HAART plus liposomal
anthracycline group developed Kaposi’s sarcoma IRIS compared
to eight out of 64 participants in the HAART alone group(RR
0.49; 95% CI 0.16 to 1.55) (Analysis 3.2).
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HAART plus chemotherapy versus HAART plus
another chemotherapy regimen
Randomised controlled trials
HAART plus paclitaxel versus HAART plus PLD
In Cianfrocca 2010, there were a total of 49 T1 Kaposi’s sarcoma
patients, with 24 in the paclitaxel group and 25 in the PLD group.
Participants were required to receive HAART (PI, a non-nucle-
oside reverse transcriptase inhibitor without a PI or both) for at
least 14 days before study enrolment.Mortality and adverse events
results were not available according to Kaposi’s sarcoma staging.
The outcomes reported were:
Progression of Kaposi’s sarcoma
One out of 24 participants had progressive disease in the pacli-
taxel group, compared to one participant out of 25 in the PLD
group(RR 1.04; 95% CI 0.07 to 15.73) (Analysis 4.1).
Clinical response (includes complete, partial and no response)
• Complete response
Two out of 24 participants had a complete response in the pacli-
taxel group, compared to one participant out of 25 in the PLD
group(RR 2.08; 95% CI 0.20 to 21.50) (Analysis 4.2).
• Partial response
Nine participants had a partial response in both the paclitaxel and
PLD groups(RR 1.04; 95% CI 0.50 to 2.17) (Analysis 4.2).
• Stable disease (no response)
There were six participants out of 24 with stable disease in the pa-
clitaxel group and 10 participants out of 25 in the PLD group(RR
0.63; 95% CI 0.27 to 1.45) (Analysis 4.2).
HAART plus pegylated liposomal doxorubicin (PLD) versus
HAART plus liposomal daunorubicin
In Cooley 2007, there were a total of 46 T1 Kaposi’s sarcoma pa-
tients, with 34 in the PLDgroup and 12 in the liposomal daunoru-
bicin group. The time interval between HAART and chemother-
apy and the HAART regimen was not described. 95% of patients
in the overall trial received HAART.
The outcomes reported were:
Progression of Kaposi’s sarcoma
There were no participants with progressive disease in either the
PLD or liposomal daunorubicin groups.
Chemotherapy versus chemotherapy in the pre-
HAART era
Randomised controlled trials
Liposomal daunorubicin versus doxorubicin, bleomycin and
vincristine (ABV)
In Gill 1996, there were a total of 227 participants, with 116 in the
liposomal daunorubicin group and 111 in the ABV group. Dur-
ing the course of the trial, 48 participants (41%) in the liposomal
daunorubicin group received concomitant zidovudine therapy, 38
(33%) were treated with didanosine and 24 (21%) received zal-
citabine. Among the participants in the ABV group, 47 (42%)
received zidovudine, 29 (26%) received didanosine and 22 (20%)
were treated with zalcitabine.
The outcomes reported were:
Mortality
Median survival time was 369 days for participants in the liposo-
mal daunorubicin group and 342 days for participants in the ABV
group. When the analysis was restricted to patients receiving prior
zidovudine, survival was improved in the liposomal daunorubicin
group as compared to the ABV group (p=0.26; individual level
data not provided).
Progression of Kaposi’s sarcoma
Nine out of 116 participants had progressive disease in the liposo-
mal daunorubicin group, compared to 11 participants out of 111
in the ABV group(RR 0.78; 95% CI 0.34 to 1.82) (Analysis 6.1).
Clinical response (includes complete, partial and no response)
• Complete response
Three out of 116 participants had a complete response in the
liposomal daunorubicin group, compared to one participant out
of 111 in the ABV group (RR2.87; 95%CI 0.3 to 27.19) (Analysis
6.2).
• Partial response
Twenty-six participants out of 116 in the liposomal daunorubicin
group had a partial response compared to 30 participants out of
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111 in the ABV group(RR 0.83; 95% CI 0.53 to 1.31) (Analysis
6.2).
• Overall response
The overall response rate (complete and partial response) in the
liposomal daunorubicin group was 29 out of 116 participants
compared to 31 out of 111 in the ABV group (RR 0.90; 95% CI
0.58 to 1.38) (Analysis 6.2).
• Stable disease (no response)
There were 72 participants out of 116 with stable disease in the
liposomal daunorubicin group and 64 participants out of 111 in
the ABV group(RR 1.08; 95% CI 0.87 to 1.33) (Analysis 6.2).
Adverse events (including toxicity and/or worsening of co-
existent disease)
One hundred and thirteen out of 116 participants in the liposomal
daunorubicin group and 107 out of 111 in the ABV group had
clinical adverse events(RR 1.01; 95% CI 0.96 to 1.06) (Analysis
6.3).
• The median time to treatment failure was 115 days in the
liposomal daunorubicin group and 99 days in the ABV group.
Quality of life
This was reported in Gill 1996. The authors reported that al-
though patients treated with ABV had a gradual decline in the
combined QOL score, the differences between the two treatment
arms were not statistically significant.
Oral etoposide versus ABV
In Olweny 2005, there were a total of 178 T1 Kaposi’s sarcoma
patients with 90 in the oral etoposide group and 88 in the ABV
group. No participant received antiretroviral therapy.
The outcomes reported were:
Mortality
There were a total of 84 deaths out of 90 participants in the oral
etoposide group compared to 76 deaths out of 88 in the ABV
group(RR 1.08; 95% CI 0.98 to 1.19) (Analysis 7.1).
Clinical response (includes complete, partial and no response)
• Complete response
There were no participants with complete response in either the
oral etoposide or ABV group.
Non-randomised trials
Bleomycin versus ABV
In Hernandez 1997, there were 24 patients with severe Kaposi’s
sarcoma in the bleomycin and ABV groups(12 in each).
The outcomes reported were:
Mortality
All 12 participants in the bleomycin only group died compared to
11 deaths out of 12 in the ABV group(RR 1.09; 95% CI 0.87 to
1.36) (Analysis 8.1).
Clinical response (includes complete, partial and no response)
• Complete response
None of the patients in either the bleomycin or ABV group had a
complete response.
• Partial response
None of the patients in the bleomycin group had a partial response
compared to four patients in the ABV group(RR 0.11; 95% CI
0.01 to 1.86) (Analysis 8.2).
• Stable disease
Seven patients in the bleomycin group compared to eight in the
ABV group had stable disease(RR 0.88; 95% CI 0.47 to 1.63)
(Analysis 8.2).
• Progression
Five participants in the bleomycin group had progressive disease
compared to none in the ABV group (RR 11; 95% CI 0.67 to
179.29) (Analysis 8.2).
Adverse events
There were five reported adverse events (fever) in the bleomycin
only group and none in the ABV group(RR 11; 95% CI 0.67 to
179.29) (Analysis 8.3).
Time to mortality
• The median survival time (in months) was 11 (6 to 20) in
the bleomycin only group and 13 (7 to 36) in the ABV group.
17Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Liposomal doxorubicin versus conservative management
(defined as bleomycin plus vinblastine, or vincristine or
single-agent antiretroviral therapy alone)
In Grünaug 1998, all 29 participants in the study were T1. There
were 20 in the liposomal doxorubicin group and 9 in the group
receiving conservative management. Seventeen out of 20 patients
in the liposomal doxorubicin group received antiretroviral therapy,
whichwasmost likely single agent, as only a subset of these patients
(2 out of the 17) received a combination of PI plus nucleosides. Of
the nine patients in the group receiving conservative management,
four had bleomycin and vinblastine or vincristine and five did not
receive chemotherapy. Two out of the five that did not receive
chemotherapy received interferon. Five of the nine patients in this
group had antiretroviral therapy alone which appears to have been
single agent therapy, although details on specific antiretrovirals
used are lacking.
The outcomes reported were:
Mortality
There were 18 deaths out of 20 in the stealth liposomal doxoru-
bicin group, while all nine patients receiving conservative man-
agement died(RR 0.93; 95% CI 0.75 to 1.15) (Analysis 9.1).
Adverse events
All 20 patients in the liposomal doxorubicin group were reported
to have adverse events (grade 1 to 4).
Time to mortality (time after diagnosis of pulmonary Kaposi’s
sarcoma to death)
The mean survival time was 11.81 months (standard deviation
(SD) 1.78) in the liposomal doxorubicin group and 4.44 months
(SD 1.68) in the conservative management group. (Cox regression
p<0.01).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
HAART + pegylated liposomal doxorubicin compared to HAART alone for the treatment of severe Kaposi’s sarcoma in HIV- infected adults (Mart in-Carbonero 2004) - RCT
Patient or population: HIV-infected adults with severe (T1) Kaposi’s sarcoma
Settings: Spain
Intervention: HAART + PLD
Comparison: HAART alone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
HAART alone HAART + PLD
Clinical response 0 per 1000 0 per 1000
(0 to 0)
RR 9
(0.61 to 133.08)
10
(1 study)
⊕⊕⊕©
moderate1
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; HAART: highly act ive ant iretroviral therapy; PLD: pegylated liposomal doxorubicin; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1There were very few events with very wide conf idence intervals.
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HAART + liposomal anthracycline compared to HAART alone for the treatment of severe Kaposi’s sarcoma in HIV- infected adults (Bower 2009) - cohort study
Patient or population: HIV-infected adults with severe (T1) Kaposi’s sarcoma
Settings: United Kingdom
Intervention: HAART + liposomal anthracycline
Comparison: HAART alone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
HAART alone HAART + liposomal an-
thracycline
M ortality 62 per 1000 77 per 1000
(22 to 274)
RR 1.23
(0.35 to 4.38)
129
(1 study)
⊕⊕⊕©
moderate1
Kaposi’s sarcoma IRIS 125 per 1000 61 per 1000
(20 to 194)
RR 0.49
(0.16 to 1.55)
129
(1 study)
⊕⊕⊕©
moderate1
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; IRIS: immune reconst itut ion inf lammatory syndrome; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1There were very few events with very wide conf idence intervals.
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HAART + paclitaxel compared to HAART + PLD for the treatment of severe Kaposi’s sarcoma in HIV- infected adults (Cianf rocca 2010) - RCT
Patient or population: HIV-infected adults with severe (T1) Kaposi’s sarcoma
Settings: USA
Intervention: HAART + paclitaxel
Comparison: HAART + PLD
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
HAART + PLD HAART + paclitaxel
Progression of Ka-
posi’s sarcoma
40 per 1000 42 per 1000
(3 to 629)
RR 1.04
(0.07 to 15.73)
49
(1 study)
⊕⊕⊕©
moderate1
Clinical response -
complete response
40 per 1000 83 per 1000
(8 to 860)
RR 2.08
(0.2 to 21.5)
49
(1 study)
⊕⊕⊕©
moderate1
Clinical response - par-
tial response
360 per 1000 374 per 1000
(180 to 781)
RR 1.04
(0.5 to 2.17)
49
(1 study)
⊕⊕⊕©
moderate1
Clinical response - sta-
ble disease
400 per 1000 248 per 1000
(108 to 580)
RR 0.63
(0.27 to 1.45)
49
(1 study)
⊕⊕⊕©
moderate1
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; HAART: highly act ive ant iretroviral therapy; PLD: pegylated liposomal doxorubicin; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1There were very few events with very wide conf idence intervals.21
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HAART + pegylated liposomal doxorubicin compared to HAART + liposomal daunorubicin for the treatment of severe Kaposi’s sarcoma in HIV- infected adults (Cooley 2007)
- RCT
Patient or population: HIV-infected adults with severe (T1) Kaposi’s sarcoma
Settings: USA
Intervention: HAART + pegylated liposomal doxorubicin
Comparison: HAART + liposomal daunorubicin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
HAART + liposomal
daunorubicin
HAART + PLD
Progression of Ka-
posi’s sarcoma
See comment See comment Not est imable 46
(1 study)
⊕⊕⊕©
moderate1
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; HAART: highly act ive ant iretroviral therapy; PLD: pegylated liposomal doxorubicin; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1There were very few events with very wide conf idence intervals.
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Liposomal daunorubicin compared to ABV for the treatment of severe Kaposi’s sarcoma in HIV- infected adults (Gill 1996) - RCT
Patient or population: HIV-infected adults with severe (T1) Kaposi’s sarcoma
Settings: USA
Intervention: l iposomal daunorubicin
Comparison: ABV
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
ABV Liposomal daunoru-
bicin
Progression of Ka-
posi’s sarcoma
99 per 1000 77 per 1000
(34 to 180)
RR 0.78
(0.34 to 1.82)
227
(1 study)
⊕⊕⊕©
moderate1
Clinical response -
complete response
9 per 1000 26 per 1000
(3 to 245)
RR 2.87
(0.3 to 27.19)
227
(1 study)
⊕⊕⊕©
moderate1
Clinical response - par-
tial response
270 per 1000 224 per 1000
(143 to 354)
RR 0.83
(0.53 to 1.31)
227
(1 study)
⊕⊕⊕©
moderate1
Clinical response -
overall response
279 per 1000 251 per 1000
(162 to 385)
RR 0.9
(0.58 to 1.38)
227
(1 study)
⊕⊕⊕©
moderate1
Clinical response - sta-
ble disease
577 per 1000 623 per 1000
(502 to 767)
RR 1.08
(0.87 to 1.33)
227
(1 study)
⊕⊕⊕©
moderate1
Adverse events 964 per 1000 974 per 1000
(925 to 1000)
RR 1.01
(0.96 to 1.06)
227
(1 study)
⊕⊕⊕©
moderate1
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
ABV: doxorubicin, bleomycin and vincrist ine; CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1There were very few events with very wide conf idence intervals.
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Oral etoposide compared to ABV for the treatment of severe Kaposi’s sarcoma in HIV- infected adults (Olweny 2005) - RCT
Patient or population: HIV-infected adults with severe (T1) Kaposi’s sarcoma
Settings: Zimbabwe
Intervention: oral etoposide
Comparison: ABV
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
ABV Oral etoposide
M ortality 864 per 1000 933 per 1000
(846 to 1000)
RR 1.08
(0.98 to 1.19)
178
(1 study)
⊕⊕⊕©
moderate1
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
ABV: doxorubicin, bleomycin and vincrist ine; CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1There were few events with wide conf idence intervals.
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Bleomycin compared to ABV for the treatment of severe Kaposi’s sarcoma in HIV- infected adults (Hernandez 1997) - non-RCT
Patient or population: HIV-infected adults with severe (T1) Kaposi’s sarcoma
Settings: Venezuela
Intervention: bleomycin
Comparison: ABV
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
ABV Bleomycin
M ortality 917 per 1000 999 per 1000
(797 to 1000)
RR 1.09
(0.87 to 1.36)
24
(1 study)
⊕©©©
very low1
Clinical response -
complete response
See comment See comment Not est imable 24
(1 study)
⊕©©©
very low1
Clinical response - par-
tial response
333 per 1000 37 per 1000
(3 to 620)
RR 0.11
(0.01 to 1.86)
24
(1 study)
⊕©©©
very low1
Clinical response - sta-
ble disease
667 per 1000 587 per 1000
(313 to 1000)
RR 0.88
(0.47 to 1.63)
24
(1 study)
⊕©©©
very low1
Clinical response - pro-
gression
0 per 1000 0 per 1000
(0 to 0)
RR 11
(0.67 to 179.29)
24
(1 study)
⊕©©©
very low1
Adverse events 0 per 1000 0 per 1000
(0 to 0)
RR 11
(0.67 to 179.29)
24
(1 study)
⊕©©©
very low1
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
ABV: doxorubicin, bleomycin and vincrist ine; CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1There were very few events with very wide conf idence intervals.
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Liposomal doxorubicin compared to bleomycin + vinblastine, vincristine or single-agent antiretroviral therapy alone (conservative management) for the treatment of severe
Kaposi’s sarcoma in HIV- infected adults (Grünaug 1998) - non-RCT
Patient or population: HIV-infected adults with severe (T1) Kaposi’s sarcoma
Settings: Germany
Intervention: l iposomal doxorubicin
Comparison: conservat ive management
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Liposomal doxorubicin Conservative manage-
ment
M ortality 1000 per 1000 930 per 1000
(750 to 1000)
RR 0.93
(0.75 to 1.15)
29
(1 study)
⊕⊕⊕©
moderate1
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1There were very few events.
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D I S C U S S I O N
Summary of main results
We included six randomised trials involving 610 HIV-infected
adults with severe Kaposi’s sarcoma (Cianfrocca 2010; Cooley
2007; Gill 1996;Martin-Carbonero 2004; Mosam 2012; Olweny
2005), and three observational studies involving a total of 182
HIV-infected adults with severe Kaposi’s sarcoma (Bower 2009;
Grünaug 1998; Hernandez 1997). None of the included studies
with the same study design compared similar interventions. Of the
nine included studies, seven included patients with a mix of mild
to moderate (T0) and severe (T1) Kaposi’s sarcoma. However,
this review was restricted to severe disease only, therefore we only
extracted data for T1 Kaposi’s sarcoma participants. There was no
universal consensus in included studies on the severity of disease
that is truly requiring of chemotherapy.
In the previous version of this Cochrane review (Dedicoat 2003),
two large randomised trials (total of 499 T0 and T1 Kaposi’s sar-
coma patients) were pooled: Northfelt 1998, comparing pegylated
liposomal doxorubicin (PLD) to doxorubicin, bleomycin and vin-
cristine (ABV), and Stewart 1998, comparing PLD to bleomycin
and vincristine. However, we excluded these studies from our up-
date of the review because the results were not available accord-
ing to Kaposi’s sarcoma stage. The pooled analysis showed similar
mortality and adverse events in both arms, but clinical response,
which included complete and partial response, favoured PLD.
Of the trials comparing highly active antiretroviral therapy
(HAART) plus chemotherapy to HAART alone for patients with
T1 Kaposi’s sarcoma, onlyMosam 2012, comparing HAART plus
ABV to HAART alone, showed a significant reduction in disease
progression in the HAART plus ABV group. There also appeared
to be a reduction in mortality and adverse events but these were
not statistically significant. It should be noted that the sickest
patients requiring urgent chemotherapy were excluded from this
trial, so it is possible that this is an underestimate of the reduction
in morbidity and possibly mortality associated with ABV when
added to HAART. Another trial involving 10 patients and com-
paring HAART plus pegylated liposomal doxorubicin to HAART
alone did not show any significant benefit in clinical response,
but was of very small sample size (Martin-Carbonero 2004). The
Bower 2009 cohort included patients on HAART alone and also
on HAART plus liposomal anthracycline but was not designed
to compare these two groups. A subset of this cohort was pre-
sented in Letang 2013 which showed a non-statistically significant
reduction in Kaposi’s sarcoma immune reconstitution inflamma-
tory syndrome (IRIS) in patients that received HAART plus li-
posomal anthracyclines, but no difference in mortality between
groups. All T1 Kaposi’s sarcoma patients in this study were meant
to receive chemotherapy as per protocol; patients who received
HAART alone were therefore exceptions.
Of the studies comparing HAART plus chemotherapy toHAART
plus a different chemotherapy regimen, Cianfrocca 2010, involv-
ing 49 T1 patients and comparing paclitaxel versus pegylated lipo-
somal doxorubicin (PLD) in patients on HAART, did not demon-
strate a difference between the two groups in disease progression
or clinical response. Another trial involving 46 T1 disease pa-
tients, comparing pegylated liposomal doxorubicin to liposomal
daunorubicin, showed no participants with progressive Kaposi’s
sarcoma disease in either group (Cooley 2007). We did not iden-
tify any randomised controlled studies from the modern HAART
era that directly compared HAART plus liposomal anthracyclines
to HAART plus ABV. In addition, we did not identify any studies
that evaluated timing of chemotherapy, i.e. whether there was a
benefit to starting chemotherapy prior to HAART as compared to
simultaneous administration.
Other studies compared different chemotherapy regimens in pa-
tients from the pre-HAARTera: Gill 1996, involving 227 patients,
compared liposomal daunorubicin to ABV and showed no signifi-
cant difference with the use of liposomal daunorubicin compared
to ABV in disease progression and overall response rate. The exclu-
sion of the Northfelt 1998 and Stewart 1998 studies is discussed
above. Olweny 2005, a trial involving 178 patients comparing
oral etoposide versus ABV in patients not on antiretroviral ther-
apy, demonstrated no significant difference in mortality between
groups. Hernandez 1997, a prospective non-randomised trial (24
patients) comparing bleomycin to ABV in the pre-HAART era,
demonstrated a highermean survival time and no reported adverse
events in the ABV group. However, there was no significant dif-
ference in disease progression between the two groups. An addi-
tional retrospective study, involving 29patients in the pre-HAART
era, showed a non-statistically significant overall mortality benefit
for liposomal doxorubicin compared to conservative management
consisting of either bleomycin plus vinblastine, vincristine or sin-
gle-agent antiretroviral therapy alone (Grünaug 1998). Liposomal
doxorubicin also showed a significant survival time benefit.
Overall completeness and applicability of
evidence
We included all studies that met the inclusion criteria for this re-
view. The trials included HIV-infected adults with severe or pro-
gressive Kaposi’s sarcoma, as defined by AIDSClinical Trial Group
T1 or progressive disease. We identified no studies on the rela-
tive timing of HAART in relationship to chemotherapy. Most of
the included studies were not designed or powered specifically to
address outcomes for patients with severe or progressive Kaposi’s
sarcoma. We were not able to do a subgroup analysis to assess if
there were particular subgroups within the population of patients
with T1 KS that would benefit more or less from chemotherapy.
Some of the outcomes addressed in the studies could not be re-
ported here because they were not presented according to disease
severity (i.e. mixed T0 and T1). The studies were conducted in
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both resource-poor and rich settings. Therefore, the findings from
this review are applicable to various settings, but identified major
gaps in the literature as above.
Quality of the evidence
We assessed the quality of evidence using the GRADE approach
and presented this in the ’Summary of findings’ tables (Summary
of findings for the main comparison; Summary of findings 2;
Summary of findings 3; Summary of findings 4; Summary of
findings 5; Summary of findings 6; Summary of findings 7;
Summary of findings 8; Summary of findings 9). The overall qual-
ity of evidence in this review can be described as moderate. We
downgraded the quality of evidence due to the small size of many
of the included studies and the low numbers of events.
Potential biases in the review process
We conducted a comprehensive search of databases and confer-
ence proceedings and we contacted experts in the field to ensure
that all relevant completed, unpublished or ongoing studies were
identified. There was no language restriction. We also contacted
study authors where possible for clarification where this was re-
quired and for unpublished data where necessary. Unpublished
data was included in the review. We minimised potential bias in
the conduct of this review by having at least two authors indepen-
dently scan through the search output, extract data and assess the
methodological quality of each study.
Agreements and disagreements with other
studies or reviews
The only data from comparison of liposomal anthracyclines with
ABV come from the pre-HAART era; in contrast to the prior
Cochrane review Dedicoat 2003, the single study in this compar-
ison included here did not show a definitive advantage from lipo-
somal anthracyclines over ABV. However, two large randomised
controlled trials on this topic had to be excluded due to their mix
of mild and severe Kaposi’s sarcoma patients.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The findings from this review suggest that highly active antiretro-
viral therapy (HAART) plus chemotherapy may be beneficial in
reducing disease progression compared to HAART alone in pa-
tients with severe or progressive Kaposi’s sarcoma. For patients on
HAART, when choosing from different chemotherapy regimens,
there was no observed difference between liposomal doxorubicin,
liposomal daunorubicin and paclitaxel.
Implications for research
Future studies should be designed and powered specifically to ad-
dress outcomes for patients with severe or progressive Kaposi’s
sarcoma and the results should be presented according to disease
severity. The delineation of what severity of disease truly needs
chemotherapy in addition to HAART, and who may be treated
with HAART alone, has yet to be firmly established. While this
review demonstrates that there is at least a treatment response ad-
vantage to adding chemotherapy to HAART in patients with T1
disease, this does not necessarily mean that ACTG tumour staging
is the most appropriate cut-off for clinicians to use when deciding
who to treat with chemotherapy. For example, there may be sub-
groups of T1 patients that could be treated with HAART alone,
or subgroups within T0 that require immediate anti-KS therapy.
The studies included in this review were not powered in such a
way to allow us to perform sub-group analyses. There is also a
need for research on the relative timing of HAART in relation to
chemotherapy for severe Kaposi’s sarcoma, and the potential role
of chemotherapy in preventing or treating Kaposi’s sarcoma im-
mune reconstitution inflammatory syndrome.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bower 2009
Methods Prospective cohort study (single centre)
Participants • HIV patients diagnosed for the first time with histologically confirmed, biopsy-
proven KS since the HAART era commenced (defined as 1 January 1996)
• 96% men
• Mean age at KS diagnosis: 39 years
• 79 T1 KS patients out of 254 patients
• 48 of 79 T1 KS patients were receiving HAART for at least 3 months at the time
of KS diagnosis
Interventions • HAART alone (163 patients: 131 were antiretroviral-naive and 32 were on
HAART at the time of KS diagnosis) (5 T1)
• HAART + chemotherapy (liposomal anthracycline): 73 patients (68 T1)
• HAART + radiotherapy: 15 patients (5 T1)
• Palliative care (1 T1)
• Surgery alone (2 patients)
Outcomes • Overall survival at 5 years
• KS IRIS
Notes This study was conducted in the UK. Median duration of follow-up was 4 years and
maximum 12 years. (Letang 2013 included Bower’s UK cohort of 213 patients of which
129 had T1 KS; Bower 2014 contains updated data from the same Bower 2009 cohort
which has already been included in the review)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not a randomised controlled trial
Allocation concealment (selection bias) High risk Not a randomised controlled trial
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding. However, the reported out-
comes are objective and not likely to be af-
fected by lack of blinding
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding. However, the reported out-
comes are objective and not likely to be af-
fected by lack of blinding
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Bower 2009 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding. However, the reported out-
comes are objective and not likely to be af-
fected by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential loss to follow-up
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk All T1 KS patients were meant to receive che-
motherapy as per protocol, patients who re-
ceived HAART alone were therefore excep-
tions
Cianfrocca 2010
Methods RCT (individual)
Participants There were a total of 49 T1 KS patients with 24 in the paclitaxel group and 25 in the
pegylated liposomal doxorubicin group
Inclusion criteria:
• Serologic diagnosis of HIV infection
• Biopsy-proven, measurable KS with any of the following features:
◦ progressive cutaneous disease
◦ symptomatic oropharyngeal or conjunctival lesions
◦ visceral involvement
◦ tumour-related lymphoedema
◦ ulceration
◦ pain
• Patients aged 18 years or above
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Exclusion criteria:
• Prior systemic cytotoxic chemotherapy for KS
• Radiotherapy could not have been delivered to marker lesions and had to be
discontinued 7 days before randomisation
• Pregnant or nursing women
• History of cardiac insufficiency (New York Heart Association Functional
Classification of II or higher)
• Active, untreated infection
• Prior or concomitant malignancy (other than curatively treated in situ cervical
carcinoma or basal/squamous cell skin carcinoma)
• Sensitivity to Escherichia coli (E. coli)-derived proteins that would preclude the use
of granulocyte colony-stimulating factor (G-CSF)
Patients were required to be receiving a stable antiretroviral drug regimen for at least 14
days before study enrolment
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Cianfrocca 2010 (Continued)
Interventions Paclitaxel (100 mg/m2), infused intravenously over 3 hours every 14 days or pegylated
liposomal doxorubicin (20 mg/m2), infused intravenously over 30 to 60 minutes every
21 days. At baseline, 53 of the 73 patients were receiving a combination HAART regimen
containing either a protease inhibitor (N = 20), a non-nucleoside reverse transcriptase
inhibitor without a protease inhibitor (N = 21) or both (N = 12)
Outcomes • Tumour response graded as complete response (CR), partial response (PR),
progressive disease (PD) and stable disease (SD) at baseline and every 3rd cycle
• Quality of life
• Adverse events evaluated and graded using the NCI Common Toxicity Criteria
(version 2)
Notes The trial was terminated prematurely because of slow accrual
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding. However, the reported outcomes are objective and
not likely to be affected by lack of blinding
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding. However, the reported outcomes are objective and
not likely to be affected by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding. However, the reported outcomes are objective and
not likely to be affected by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No significant differential loss to follow-up. Intention-to-treat
analysis described
Selective reporting (reporting bias) Low risk There is no evidence of selective outcome reporting
Other bias Unclear risk Trial terminated prematurely due to slow accrual
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Cooley 2007
Methods Double-blinded, multicentre RCT
Participants 79 patients with AIDS-related KS. 46 patients had T1 disease with 34 in the PLD group
and 12 in the liposomal daunorubicin group
Inclusion criteria:
• AIDS-related KS requiring systemic chemotherapy
• Life expectancy of at least 120 days
• At least 5 measurable mucocutaneous KS lesions
• 1 or more of the following symptoms:
◦ KS-associated oedema that impaired functional activity of the extremities,
groin or face
◦ Symptomatic evaluable pulmonary KS or gastrointestinal KS that had been
documented by bronchoscopy and endoscopy respectively within 3 months of entering
the trial, and was definitely associated with KS and not with any other manifestation of
HIV disease
◦ KS-associated pain reported by the patient to be moderate or severe despite
analgesic use
◦ KS lesions that, according to the patient, were disfiguring and that impaired
self image or daily activities
• Patients were also required to have a left ventricular ejection fraction (LVEF) ≥
50%; a Karnofsky performance status (KPS)≥ 40%; and a haemoglobin concentration
≥ 9 g/dl, neutrophil count ≥ 1200 cells/mm3, a platelet count ≥ 75,000/mm3 and
bilirubin and creatinine levels less than 2 times the upper limit of normal
Exclusion criteria:
• Patients who received anti-KS therapy within 14 days of study entry or had
received treatment with pegylated liposomal doxorubicin or liposomal daunorubicin at
any time prior to study entry
• Presentation with clinically significant cardiac disease as defined by
histopathologic evidence of anthracycline-induced cardiomyopathy, LVEF < 50% or
abnormal wall motion
• Onset of or increased therapy for an opportunistic infection within 4 weeks of
study entry
• Presence of significant non-KS-related pulmonary insufficiency (oxygen
saturation < 90%)
• Presence of other active malignancies except basal or squamous cell carcinoma of
the skin or in situ cervical or anal carcinoma
• Neuropsychiatric history or altered mental status that prevented informed consent
or compliance with the protocol requirements
• Pregnancy or breastfeeding, or any women of child-bearing age not using a
medically proven method of birth control
Interventions Pegylated liposomal doxorubicin (20 mg/m2; n = 60) versus liposomal daunorubicin (40
mg/m2; n = 20) as a 60-minute intravenous infusion every 2 weeks for 6 cycles
Patients were assessed at ≤ 30 days before treatment, at each of the 6 treatment cycles
and at the end of the study
76 patients in the study received HAART
Outcomes Tumour response: complete response (CR), partial response (PR), progressive disease
(PD), stable disease (SD); time to progression; survival; adverse events recorded and
graded using the National Cancer Institute Common Toxicity Criteria
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Cooley 2007 (Continued)
Notes This study was conducted in the USA
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk An independent AIDS expert without the knowl-
edge of the patient evaluated the outcome
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding. However, the reported outcomes are
objective and not likely to be affected by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk An independent AIDS expert evaluated the out-
come
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was no differential loss to follow-up
Selective reporting (reporting bias) Low risk There is no evidence of selective outcome report-
ing
Other bias Low risk No significant baseline differences between arms
Gill 1996
Methods RCT (individual)
Participants Inclusion criteria:
• Serologic documentation of HIV infection and biopsy-proven KS
• Advanced KS defined as:
◦ the presence of ≥ 25 mucocutaneous lesions;
◦ symptomatic visceral involvement; or
◦ the presence of tumour-associated lymphoedema
• Age ≥18 years
• Entry Karnofsky performance status (KPS) score ≥ 70%
• No prior systemic chemotherapy
• Prior radiation or other local therapies (cryotherapy or intralesional vinblastine)
had to be discontinued ≥ 14 days before study enrolment
• Patients were required to have a left ventricular ejection fraction (LVEF) of ≥
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Gill 1996 (Continued)
45% measured by multiple-gated acquisition (MUGA) scan or by echocardiogram
• Adequate bone marrow function (absolute neutrophil count (ANC) ≥ 1.5 x 109/
l, platelet count ≥ 75 x 109/l, and haemoglobin level ≥ 85 g/l), renal function (serum
creatinine level ≤ 2.0 mg/dl) and hepatic function (bilirubin level ≤ 1.5 times the
upper limit of normal and AST≤ 3.0 times upper limit of normal)
Exclusion criteria:
• Acute intercurrent infection
• Active symptomatic AIDS-defining opportunistic infection
• Symptomatic peripheral neuropathy
• Concurrent therapy with ganciclovir or systemic corticosteroids
• Other primary malignant tumours (except basal cell skin carcinoma or carcinoma
in situ of the cervix)
Interventions Patients received liposomal daunorubicin at a dose of 40 mg/m2 infused over 30 to
60 minutes, or a regimen of doxorubicin 10 mg/m2, bleomycin 15 U and vincristine
1 mg (ABV) every 2 weeks intravenously on an outpatient basis. Cycles were repeated
every 14 days provided absolute neutrophil count (ANC) was ≥0.75 x 109/l and the
platelet count ≥75 x 109/l. Patients whose ANC decreased to less than 0.75 x 109/l had
chemotherapywithheld and could receiveG-CSF to enable resumption of chemotherapy
once the ANC had returned to ≥ 0.75 x 109/l
During the course of the trial, 48 liposomal daunorubicin patients (41%) received con-
comitant zidovudine therapy, 38 (33%) were treated with didanosine and 24 (21%)
received zalcitabine. Among the ABV patients, 47 (42%) received zidovudine, 29 (26%)
received didanosine and 22 (20%) were treated with zalcitabine
Outcomes • Tumour responses were categorised based on modified AIDS Clinical Trials
Group (ACTG) criteria as follows: complete response (CR), partial response (PR),
progressive disease (PD), stable disease (SD)
• Quality of life
• Time to progression
• Adverse events
Notes This study was conducted in the USA
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Permuted-block randomisation
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding. However, the reported outcomes are objective and
not likely to be affected by lack of blinding
Blinding of participants and personnel
(performance bias)
Low risk No blinding. However, the reported outcomes are objective and
not likely to be affected by lack of blinding
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Gill 1996 (Continued)
All outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding. However, the reported outcomes are objective and
not likely to be affected by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential loss to follow-up
Selective reporting (reporting bias) Low risk There is no evidence of selective outcome reporting
Other bias Low risk No significant baseline differences between arms
Grünaug 1998
Methods Retrospective, cohort, multicentre study
Participants 29 AIDS patient with bronchoscopy or histologically confirmed pulmonary KS patients.
All participants had T1 KS
Interventions Group 1: (n = 20) stealth liposomal doxorubicin (SL-DOX) 20 mg/m2 every 2nd week
Group 2: (n = 9) no SL-DOX (conservative management)
Of the 20 patients in group 1, 17 had ARV therapy; of the 9 patients in group 2, 4
had bleomycin and vincristine or vinblastine while the remaining 5 patients had no
chemotherapy
Outcomes Survival, clinical response
Notes This study was conducted in Munich, Germany
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not a randomised controlled trial
Allocation concealment (selection bias) High risk Not a randomised controlled trial
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding. However, the reported out-
comes are objective and not likely to be af-
fected by lack of blinding
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding. However, the reported out-
comes are objective and not likely to be af-
fected by lack of blinding
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Grünaug 1998 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding. However, the reported out-
comes are objective and not likely to be af-
fected by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential loss to follow-up
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
Other bias Low risk No other potential sources of bias identified
Hernandez 1997
Methods Prospective non-randomised trial
Participants Inclusion criteria:
• Homosexual or bisexual men
• Aged 21 to 45 years
• Positive ELISA test for HIV
• Confirmatory biopsy for KS
Patients clinically staged according to AIDS Clinical Trial Group (ACTG) criteria into
“good risk” and “poor risk”
Interventions • 10 patients with limited KS received alpha-2 interferon (5 million units
subcutaneously 3 times weekly) plus zidovudine (AZT 500 mg daily)
• 24 patients with advanced KS, 12 in each group, received either intramuscular
bleomycin 5 mg daily every 2 weeks for 3 days or low-dose doxorubicin (20 mg/m2),
bleomycin (10 mg/m2) and vincristine (1.4 mg/m2, 2 mg max) every 3 weeks
• 10 “poor risk” patients received no treatment due to financial constraint
Patients were followed until death
Outcomes Clinical response: complete remission, partial remission, stable disease, progression;mor-
tality; survival; adverse events
Notes This study was conducted in Venezuela
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not a randomised controlled trial
Allocation concealment (selection bias) High risk Not a randomised controlled trial
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding not described
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Hernandez 1997 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential loss to follow-up
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
Other bias Unclear risk No other potential sources of bias identified
Martin-Carbonero 2004
Methods Randomised, open-label, multicentre study
Participants Inclusion criteria:
• Biopsy-confirmed HIV-KS-affected patients without HIV-RNA control (naive,
without HAART or with failing treatment)
• At least 10 cutaneous lesions or mucosal or visceral involvement
Exclusion criteria:
• Life-threatening KS
Interventions 25 treatment and non-treatment-naive HIV patients with moderate to advanced KS
randomly assigned to receive:
• Intravenous PLD (group A) administered at doses of 20 mg/m2 every 3 weeks
compared with HAART alone (group B)
5 of 13 patients in group A and 5 of 15 patients in group B were ACTG T1 KS patients
Outcomes Response rate: complete response, partial response, disease progression
Notes This study was conducted in Spain. Duration of follow-up was 48 weeks
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence
Allocation concealment (selection bias) Unclear risk Not described
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Martin-Carbonero 2004 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding. However, the reported out-
comes are objective and not likely to be af-
fected by lack of blinding
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding. However, the reported out-
comes are objective and not likely to be af-
fected by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding. However, the reported out-
comes are objective and not likely to be af-
fected by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis done. No differ-
ential loss to follow-up
Selective reporting (reporting bias) Low risk There is no evidence of selective outcome
reporting
Other bias High risk The prevalence of previous opportunis-
tic infections was higher in patients allo-
cated to the pegylated liposomal doxoru-
bicin group
Mosam 2012
Methods Open-label, prospective, single-centre RCT
Participants Inclusion criteria:
• Treatment-naive, proven HIV and histologically confirmed KS (no prior KS or
HIV therapy)
Exclusion criteria:
• KS requiring urgent chemotherapy (i.e. symptomatic visceral disease or fungating
lesions)
• Peripheral neuropathy
• Clinical congestive heart disease or ejection fraction < 50%
• Neutrophil count of < 1000 units per litre
• Haemoglobin < 9.0 gm/dl, platelet count of < 75 x 109 per litre
• Serum creatinine > 114.4 µmol/l
• Direct serum bilirubin > 85 µmol/l, aspartate aminotransferase or alanine
aminotransferase > 2.5 times the normal range
• Intensive phase of tuberculosis therapy
Interventions HAART alone or HAART and chemotherapy
• HAART arm received fixed-dose combination of stavudine (40 mg), lamivudine
(150 mg) and nevirapine 200 mg
• Chemotherapy consisted of doxorubicin (20 mg/m2 IV), bleomycin (10 U/m2
IV) and vincristine (1.4 mg/m2 IV, capped at 2 mg) (ABV) every 3 weeks, started
within the first month of initiation of HAART, with the goal of continuing
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Mosam 2012 (Continued)
chemotherapy for 2 cycles beyond maximal response
Outcomes • Primary outcome:
◦ Overall KS response using AIDS Clinical Trial Group criteria 12 months
after HAART initiation
• Secondary outcome:
◦ Time to response
◦ Progression-free survival
◦ Adverse events
◦ HIV control
◦ CD4 reconstitution
◦ Adherence
◦ Quality of life
KS responses were graded as complete, partial, stable disease and progressive disease using
ACTG criteria (for ACTG KS Response Criteria)
Toxicities were graded using the Division of AIDS (DAIDS) toxicity scale
Adherence was assessed by a 7-day recall questionnaire at week 2, week 4 and then
monthly
Previously validated quality of life (QOL) questionnaires (EORTC QOL-30) measured
6 functioning scales
Notes Although the planned chemotherapy protocol was ABV, oral etoposide (50 to 100 mg
for 1 to 21 days of a 28-day cycle) was used as an alternative therapy in the event of
difficulties with the chemotherapy drug supply or intravenous administration during
the protocol. Etoposide was started at 50 mg daily but could be escalated to 100 mg
in patients in subsequent cycles with inadequate KS tumour regression and no limiting
toxicities
This study included a mix of T0 and T1 participants, but only T1 disease was included
in our analysis (data provided by communication with the author)
Results from Bihl 2007 were included in this study
Study was conducted in South Africa. Duration of follow-up was 12 months
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of computed-generated random num-
bers
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding. However, the reported out-
comes are objective and not likely to be af-
fected by lack of blinding
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding. However, the reported out-
comes are objective and not likely to be af-
fected by lack of blinding
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Mosam 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding. However, the reported out-
comes are objective and not likely to be af-
fected by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors used an intention to treat anal-
ysis. There was no differential loss to fol-
low-up
Selective reporting (reporting bias) Low risk There is no evidence of selective outcome
reporting
Other bias High risk There was some baseline imbalance. Pa-
tients randomised to CXT but not receiv-
ing chemotherapy had low baseline CD4
counts (median, 77 cells/ml), compared
with those receiving chemotherapy (me-
dian, 249 cells/ml). When ABV was not
available, oral Etoposide was given. This al-
ternative chemotherapy regimen was used
in 31% of patients that received chemo-
therapy overall
Olweny 2005
Methods 4-arm, randomised, open-label RCT
Participants Inclusion criteria
• Histologically confirmed KS
• HIV-positive adults
• ECOG performance status of ≤ 3
• Systemic symptoms such as fever, weight loss and diaphoresis
• Other symptoms including diarrhoea, dyspnoea, as well as past histories of
pneumonia, sexually transmitted diseases and opportunistic infections
• Cachexia, lymphadenopathy, oral and palatal lesions, skin lesions, chest signs and
opportunistic fungal infections
• Patients with stage III and IV disease
Patients were not on any antiretroviral therapy
Interventions • Group 1: supportive care only
• Group 2: supportive care + single-agent oral etoposide at a dose of 100 mg (two
50 mg capsules) daily for 5 days, repeated monthly
• Group 3: supportive care + ABV: combination of actinomycin-D (2 mg/m2, IV
every 4 weeks), bleomycin (15 mg/m2, IV every 4 weeks) and vincristine (1.4 mg/m2,
IV every 4 weeks)
• Group 4: radiotherapy + supportive care. They were treated on 60-cobalt single
field or parallel opposed pair of fields, depending on site and volume of disease
There were a total of 178 T1KS patients in groups 2 and 3, with 90 in the oral etoposide
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Olweny 2005 (Continued)
group and 88 in the ABV group. No participant received antiretroviral therapy
Outcomes Primary outcome:
• Quality of life (QOL)
Secondary outcomes:
• Tumour response: complete response (CR), partial response (PR), progressive
disease (PD), stable disease (SD)
• Survival
• Toxicity
QOL was measured by the functional living index-cancer (FLI-C) and supplemented by
the Kaposi’s sarcoma module (KSM)
Notes Study was conducted in a resource-poor setting: Harare, Zimbabwe. Patients were fol-
lowed up until death
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation cards
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No blinding, reported primary outcome (QOL)
is subjective. However, the other reported out-
comes are objective and not likely to be affected
by lack of blinding
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding, reported primary outcome (QOL)
is subjective. However, the other reported out-
comes are objective and not likely to be affected
by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No blinding, reported primary outcome (QOL)
is subjective. However, the other reported out-
comes are objective and not likely to be affected
by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors imputed missing data; no differen-
tial loss to follow-up
Selective reporting (reporting bias) Low risk There is no evidence of selective outcome re-
porting
Other bias Low risk Differences between arms were adjusted for in
the analysis
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ABV: doxorubicin, bleomycin and vincristine
AIDS: acquired immunodeficiency syndrome
ANC: absolute neutrophil count
ART: antiretroviral therapy ARV: antiretroviral
ACTG: AIDS Clinical Trial Group
AZT: zidovudine CXT: chemotherapy
ECOG: Eastern Cooperative Oncology Group
ELISA: enzyme-linked immunosorbent assay
G-CSF: granulocyte colony-stimulating factor
HAART: highly active antiretroviral therapy
HIV: human immunodeficiency virus
IRIS: immune reconstitution inflammatory syndrome
IV: intravenous
KPS: Karnofsky performance status
KS: Kaposi’s sarcoma
LVEF: left ventricular ejection fraction
PLD: pegylated liposomal doxorubicin RNA: ribonucleic acid
QOL: quality of life
RCT: randomised controlled trial
SL-DOX: stealth liposomal doxorubicin
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Asiimwe 2012 This was a cohort of 17 patients with prevalent KS and 18 patients with incident KS in Tororo, Uganda.
There was limited access to chemotherapy. All patients initially received the same ART regimen (NNRTI)
and patients were only switched to a PI if they were considered treatment failures
Autier 2005 This was a retrospective, observational study of docetaxel in anthracycline-pretreated AIDS-related KS.
There was no comparison group
Bihl 2007 This was a subset of the Mosam 2012 study, which has already been included in the review
Bodsworth 2001 This was a phase III, vehicle-controlled, multi-centred study of topical alitretinoin gel 0.1% in cutaneous
AIDS-related KS. The participants included were a mix of visceral and cutaneous KS. There was no relevant
comparison for this review
Bonhomme 1991 This was a randomised controlled trial of topical treatment of epidemic KS with all-trans-retinoic acid.
The authors included participants with different stages of KS. Outcomes were not separated by stage of the
disease
Bonhomme 1994 This was a randomised trial assessing the treatment of AIDS-associated KS with oral tretinoin. We could
not retrieve the full-text article
Borok 2010 This was a cohort of 90 ART-naive adults with biopsy-proven KS. All patients received ART, and then
patients received additional treatment at the discretion of their provider with chemotherapy in 56% of
cases and adjunctive radiotherapy in 24% of cases. Outcomes were not separated by stage of the disease
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Cattelan 2005 We could not obtain the full-text article to help us make a decision
Duvic 2000 This was an open-label, within-patient, controlled, dose-escalating phase 1 and 2 clinical trial to evaluate
the efficacy and safety of topical alitretinoin gel in cutaneous KS. There was no relevant comparison for
this review
Gelmann 1987 This was a randomised trial of combination chemotherapy versus recombinant alpha interferon for KS.
There was no relevant comparison for this review
Gill 1991 This was a randomised trial of systemic treatment of AIDS-related KS. Patients with extensive mucocuta-
neous KS or visceral involvement were randomised to treatment with low-dose adriamycin (doxorubicin,
20 mg/m2) alone (31 cases) or in combination with bleomycin and vincristine (ABV) (30 cases). Results
were not presented by KS disease stage. Attempts to contact the study author were not successful
Harrison 1998 Biopsy confirmation of KS was not an absolute requirement for inclusion in the study
Hernandez 1996 This is an observational study evaluating the treatment of epidemic KS with bleomycin or combination of
doxorubicin, bleomycin and vincristine. Results for outcomes are not reported by stage of KS disease
Ireland-Gill 1992 This was an observational study of the treatment of AIDS-related KS using bleomycin-containing com-
bination chemotherapy regimens. We could not obtain the full-text article. The staging of KS was not
mentioned in the abstract and the results presented were not separated by KS stage
Koon 2011 This phase-II study of 23 HIV patients with KS had an intra-patient vehicle control design comparing
topically administered halofuginone, an angiogenesis inhibitor that inhibits collagen type-I and matrix
metalloproteinases (MMPs), with vehicle ointment. There was no relevant comparison for this review
Krigel 1988 This was an prospective, observational study of the treatment of epidemic KS with a combination of
interferon-alpha 2b and etoposide. There was no comparison group
Lane 1989 This was a phase II, randomised, placebo-controlled trial of zidovudine in patients with HIV infection and
KS. Results are not available by KS disease stage
Lasso 2003 This was a retrospective review of HIV patients with KS seen at a public hospital and at a HIV clinic and
subjected to antiretroviral treatment and chemotherapy. Results are not available by KS disease stage
Letang 2013 Letang et al followed 4 cohorts of HIV-positive patients diagnosed with KS in a) Chelsea and Westminster
Hospital, London, UK; b) King Edward VIII Hospital, Durban, South Africa; c) Parirenyatwa Hospital
Kaposi Sarcoma Clinic, Harare, Zimbabwe; and d) Manhica Health Research Centre, Manhica, Mozam-
bique. Only the UK cohort included participants who were exposed to the intervention of interest (ART
plus chemotherapy). The UK cohort study is already included in this review. See Bower 2009 (IRIS and
mortality data were provided by Letang 2013)
Lichterfeld 2005 This was an observational study of treatment of HIV-1-associated KSwith pegylated liposomal doxorubicin
and HAART simultaneously. Participants with early-stage KS received etoposide while those with late-stage
KS received ABV
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(Continued)
Lim 2005 This was an observational study of a weekly dose of docetaxel in the treatment of advanced-stage AIDS-
related KS. There was no comparison group
Monticelli 2000 This study presented either a case series or cohort (design not specified) of 18 HIV patients diagnosed with
KS between 1994 and 1997 in Argentina. Staging of KS was specified as stages I to IV, but definition of
these stages was not clearly laid out (another paper which used ACTG staging was referenced)
Mussini 2008 This is a cohort study evaluating the effects of different HAART regimens on AIDS-related KS. Staging of
KS and results by disease stage are not available
Nguyen 2008 This was a cohort study characterising the predictors of clinical response in patients with KS. Multiple
HAART and chemotherapy regimens were used. Comparison not clear
Northfelt 1998 This was a randomised clinical trial of pegylated liposomal doxorubicin versus doxorubicin, bleomycin and
vincristine in the treatment of AIDS-related KS. Staging of KS for included participants (mixed T0, T1)
and results by KS disease stage are not available. We contacted the author to provide additional information
but were not successful
Noy 2005 This RCT of 202 HIV patients with KS compared synthetic dipeptide IM862 (L-glutamine L-tryptophan)
plus ART to placebo plus ART. Patients with symptomatic visceral disease or who required chemotherapy
were excluded
Nunez 2001 This was a prospective, non-comparative study of response to liposomal doxorubicin and clinical outcome
of HIV-1-infected patients with KS receiving highly active antiretroviral therapy. There was no comparison
group
Opravil 1999 Biopsy confirmation of KS was not an absolute requirement. Patients were allowed to change regimen if
they did not tolerate the regimen to which they had been randomised. The comparison groups were not
well matched for severity of disease
Osoba 2001 This was a randomised trial of the effect of pegylated liposomal doxorubicin versus doxorubicin, bleomycin
and vincristine on health-related quality of life in AIDS-related KS: staging of KS and results by disease
stage are not available
Palmieri 2006 Thiswas a cohort study of evaluating the effects ofHAART+ liposomal anthracycline for treating pulmonary
KS. All participants received the same treatment. There was no comparison group
Ramirez-Amador 2002 This was a randomised clinical trial of intralesional vinblastine versus 3% sodium tetradecyl sulfate for the
treatment of oral KS. There was no relevant comparison for this review
Rosenthal 2002 This was an observational study of the efficacy and tolerance of liposomal daunorubicin in combination
with HAART versus HAART alone in the treatment of AIDS-associated KS. The authors did not present
results by comparison of the two groups
Shepherd 1998 This was a prospective, randomised trial of 2 dose levels of interferon alfa with zidovudine for the treatment
of KS associated with HIV infection. There was no relevant comparison for this review
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(Continued)
Singh 2008 This was a phase 1 dose study of hypofractionated radiation therapy in the treatment of epidemic KS: a
prospective randomised trial
Stelzer 1993 This was a randomised, prospective, phase 1 dose study of radiation therapy for AIDS-associated KS
Stewart 1998 This was a randomised, comparative trial of pegylated liposomal doxorubicin versus bleomycin and vin-
cristine in the treatment of AIDS-related KS. We contacted the author to obtain additional information.
However, he no longer has access to the original data
Strother 2010 This was a retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated KS
in western Kenya. There was no comparison group
Tavio 1996 This was a prospective, multi-institutional Italian study that evaluated the efficacy and toxicity of combi-
nation chemotherapy with doxorubicin, bleomycin and vindesine (ABVi) in patients with progressive and
extensive HIV-related KS. There was no comparison group
Tulpule 2002 This was a multicentre, phase 2 trial of low-dose paclitaxel in patients with advanced AIDS-related KS. All
participants were given the same dose of paclitaxel
Uthayakumar 1996 This was a randomised, cross-over comparison of liposomal daunorubicin versus observation for early KS.
Only participants with T0 KS were included
Walmsley 1999 Thiswas a 12-week,multicentre, randomised, double-blind, vehicle-controlled safety and efficacy evaluation
of topical alitretinoin 0.1% gel applied to cutaneous KS lesions conducted inHIV-infected patients. Staging
of KS was not available and the results were not available by staging
Zhong 2012 This was an observational study of etoposide, vincristine, doxorubicin and dexamethasone (EVAD) com-
bination chemotherapy as second-line treatment for advanced AIDS-related KS. There was no comparison
group
ABV: doxorubicin, bleomycin and vincristine
ACTG: AIDS Clinical Trial Group AIDS: acquired immunodeficiency syndrome
ART: antiretroviral therapy
HAART: highly active antiretroviral therapy
HIV: human immunodeficiency virus
IRIS: immune reconstitution inflammatory syndrome
KS: Kaposi’s sarcoma NNRTI: non-nucleoside reverse transcriptase inhibitor
PI: protease inhibitor
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. HAART + ABV versus HAART alone (RCT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Progressive disease 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.1 [0.01, 0.75]
3 Clinical response 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Complete response 1 100 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.64, 6.22]
3.2 Partial response 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [1.01, 2.91]
3.3 Stable disease 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.06 [0.00, 0.99]
3.4 Overall response
(complete and partial)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.78 [1.16, 2.72]
4 Adverse events 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.59, 1.32]
Comparison 2. HAART + pegylated liposomal doxorubicin versus HAART alone (RCT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical response 1 10 Risk Ratio (M-H, Fixed, 95% CI) 9.0 [0.61, 133.08]
Comparison 3. HAART + liposomal anthracycline versus HAART alone (cohort study)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 129 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.35, 4.38]
2 KS IRIS 1 129 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.16, 1.55]
Comparison 4. HAART + paclitaxel versus HAART + pegylated liposomal doxorubicin (RCT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Progression of KS 1 49 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.07, 15.73]
2 Clinical response 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Complete response 1 49 Risk Ratio (M-H, Fixed, 95% CI) 2.08 [0.20, 21.50]
2.2 Partial response 1 49 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.50, 2.17]
2.3 Stable disease 1 49 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.27, 1.45]
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Comparison 5. HAART + pegylated liposomal doxorubicin versus HAART + liposomal daunorubicin (RCT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Progression of KS 1 46 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Liposomal daunorubicin versus ABV (RCT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Progression of KS 1 227 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.34, 1.82]
2 Clinical response 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Complete response 1 227 Risk Ratio (M-H, Fixed, 95% CI) 2.87 [0.30, 27.19]
2.2 Partial response 1 227 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.53, 1.31]
2.3 Overall response 1 227 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.58, 1.38]
2.4 Stable disease 1 227 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.87, 1.33]
3 Adverse events 1 227 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.96, 1.06]
Comparison 7. Oral etoposide versus ABV (RCT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 178 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.98, 1.19]
Comparison 8. Bleomycin versus ABV (non-RCT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 24 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.87, 1.36]
2 Clinical response 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Complete response 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Partial response 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 1.86]
2.3 Stable disease 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.47, 1.63]
2.4 Progression 1 24 Risk Ratio (M-H, Fixed, 95% CI) 11.0 [0.67, 179.29]
3 Adverse events 1 24 Risk Ratio (M-H, Fixed, 95% CI) 11.0 [0.67, 179.29]
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Comparison 9. Liposomal doxorubicin versus conservative management (non-RCT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.75, 1.15]
Analysis 1.1. Comparison 1 HAART + ABV versus HAART alone (RCT), Outcome 1 Mortality.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 1 HAART + ABV versus HAART alone (RCT)
Outcome: 1 Mortality
Study or subgroup
HAART plus
chemother-
apy HAART alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mosam 2012 11/50 12/50 0.92 [ 0.45, 1.88 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours HAART plus chemo Favours HAART alone
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Analysis 1.2. Comparison 1 HAART + ABV versus HAART alone (RCT), Outcome 2 Progressive disease.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 1 HAART + ABV versus HAART alone (RCT)
Outcome: 2 Progressive disease
Study or subgroup
HAART plus
chemother-
apy HAART alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mosam 2012 1/50 10/50 100.0 % 0.10 [ 0.01, 0.75 ]
Total (95% CI) 50 50 100.0 % 0.10 [ 0.01, 0.75 ]
Total events: 1 (HAART plus chemotherapy), 10 (HAART alone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours HAART plus chemo Favours HAART alone
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Analysis 1.3. Comparison 1 HAART + ABV versus HAART alone (RCT), Outcome 3 Clinical response.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 1 HAART + ABV versus HAART alone (RCT)
Outcome: 3 Clinical response
Study or subgroup
HAART plus
chemother-
apy HAART alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Complete response
Mosam 2012 8/50 4/50 100.0 % 2.00 [ 0.64, 6.22 ]
Subtotal (95% CI) 50 50 100.0 % 2.00 [ 0.64, 6.22 ]
Total events: 8 (HAART plus chemotherapy), 4 (HAART alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
2 Partial response
Mosam 2012 24/50 14/50 100.0 % 1.71 [ 1.01, 2.91 ]
Subtotal (95% CI) 50 50 100.0 % 1.71 [ 1.01, 2.91 ]
Total events: 24 (HAART plus chemotherapy), 14 (HAART alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.046)
3 Stable disease
Mosam 2012 0/50 8/50 100.0 % 0.06 [ 0.00, 0.99 ]
Subtotal (95% CI) 50 50 100.0 % 0.06 [ 0.00, 0.99 ]
Total events: 0 (HAART plus chemotherapy), 8 (HAART alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.049)
4 Overall response (complete and partial)
Mosam 2012 32/50 18/50 100.0 % 1.78 [ 1.16, 2.72 ]
Subtotal (95% CI) 50 50 100.0 % 1.78 [ 1.16, 2.72 ]
Total events: 32 (HAART plus chemotherapy), 18 (HAART alone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0078)
0.01 0.1 1 10 100
Favours HAART plus chemo Favours HAART alone
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Analysis 1.4. Comparison 1 HAART + ABV versus HAART alone (RCT), Outcome 4 Adverse events.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 1 HAART + ABV versus HAART alone (RCT)
Outcome: 4 Adverse events
Study or subgroup
HAART plus
chemother-
apy HAART alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mosam 2012 23/50 26/50 100.0 % 0.88 [ 0.59, 1.32 ]
Total (95% CI) 50 50 100.0 % 0.88 [ 0.59, 1.32 ]
Total events: 23 (HAART plus chemotherapy), 26 (HAART alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours HAART plus chemo Favours HAART alone
Analysis 2.1. Comparison 2 HAART + pegylated liposomal doxorubicin versus HAART alone (RCT),
Outcome 1 Clinical response.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 2 HAART + pegylated liposomal doxorubicin versus HAART alone (RCT)
Outcome: 1 Clinical response
Study or subgroup HAART + PLD HAART alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martin-Carbonero 2004 4/5 0/5 100.0 % 9.00 [ 0.61, 133.08 ]
Total (95% CI) 5 5 100.0 % 9.00 [ 0.61, 133.08 ]
Total events: 4 (HAART + PLD), 0 (HAART alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours HAART + PLD Favours HAART alone
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Analysis 3.1. Comparison 3 HAART + liposomal anthracycline versus HAART alone (cohort study),
Outcome 1 Mortality.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 3 HAART + liposomal anthracycline versus HAART alone (cohort study)
Outcome: 1 Mortality
Study or subgroup
HAART +
liposomal
anthrac HAART alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bower 2009 5/65 4/64 100.0 % 1.23 [ 0.35, 4.38 ]
Total (95% CI) 65 64 100.0 % 1.23 [ 0.35, 4.38 ]
Total events: 5 (HAART + liposomal anthrac), 4 (HAART alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours HAART + liposomal Favours HAART alone
Analysis 3.2. Comparison 3 HAART + liposomal anthracycline versus HAART alone (cohort study),
Outcome 2 KS IRIS.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 3 HAART + liposomal anthracycline versus HAART alone (cohort study)
Outcome: 2 KS IRIS
Study or subgroup
HAART +
liposomal
anthrac HAART alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bower 2009 4/65 8/64 100.0 % 0.49 [ 0.16, 1.55 ]
Total (95% CI) 65 64 100.0 % 0.49 [ 0.16, 1.55 ]
Total events: 4 (HAART + liposomal anthrac), 8 (HAART alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours HAART + liposomal Favours HAART alone
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Analysis 4.1. Comparison 4 HAART + paclitaxel versus HAART + pegylated liposomal doxorubicin (RCT),
Outcome 1 Progression of KS.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 4 HAART + paclitaxel versus HAART + pegylated liposomal doxorubicin (RCT)
Outcome: 1 Progression of KS
Study or subgroup Paclitaxel PLD Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cianfrocca 2010 1/24 1/25 100.0 % 1.04 [ 0.07, 15.73 ]
Total (95% CI) 24 25 100.0 % 1.04 [ 0.07, 15.73 ]
Total events: 1 (Paclitaxel), 1 (PLD)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours paclitaxel Favours PLD
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Analysis 4.2. Comparison 4 HAART + paclitaxel versus HAART + pegylated liposomal doxorubicin (RCT),
Outcome 2 Clinical response.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 4 HAART + paclitaxel versus HAART + pegylated liposomal doxorubicin (RCT)
Outcome: 2 Clinical response
Study or subgroup Paclitaxel PLD Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Complete response
Cianfrocca 2010 2/24 1/25 100.0 % 2.08 [ 0.20, 21.50 ]
Subtotal (95% CI) 24 25 100.0 % 2.08 [ 0.20, 21.50 ]
Total events: 2 (Paclitaxel), 1 (PLD)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
2 Partial response
Cianfrocca 2010 9/24 9/25 100.0 % 1.04 [ 0.50, 2.17 ]
Subtotal (95% CI) 24 25 100.0 % 1.04 [ 0.50, 2.17 ]
Total events: 9 (Paclitaxel), 9 (PLD)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
3 Stable disease
Cianfrocca 2010 6/24 10/25 100.0 % 0.63 [ 0.27, 1.45 ]
Subtotal (95% CI) 24 25 100.0 % 0.63 [ 0.27, 1.45 ]
Total events: 6 (Paclitaxel), 10 (PLD)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Chi2 = 1.36, df = 2 (P = 0.51), I2 =0.0%
0.01 0.1 1 10 100
Favours paclitaxel Favours PLD
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Analysis 5.1. Comparison 5 HAART + pegylated liposomal doxorubicin versus HAART + liposomal
daunorubicin (RCT), Outcome 1 Progression of KS.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 5 HAART + pegylated liposomal doxorubicin versus HAART + liposomal daunorubicin (RCT)
Outcome: 1 Progression of KS
Study or subgroup PLD
Liposomal
daunoru-
bicin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cooley 2007 0/34 0/12 Not estimable
Total (95% CI) 34 12 Not estimable
Total events: 0 (PLD), 0 (Liposomal daunorubicin)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PLD Favours liposomal daunoru
Analysis 6.1. Comparison 6 Liposomal daunorubicin versus ABV (RCT), Outcome 1 Progression of KS.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 6 Liposomal daunorubicin versus ABV (RCT)
Outcome: 1 Progression of KS
Study or subgroup
Liposomal
daunoru-
bicin ABV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gill 1996 9/116 11/111 100.0 % 0.78 [ 0.34, 1.82 ]
Total (95% CI) 116 111 100.0 % 0.78 [ 0.34, 1.82 ]
Total events: 9 (Liposomal daunorubicin), 11 (ABV)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours liposomal Favours ABV
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Analysis 6.2. Comparison 6 Liposomal daunorubicin versus ABV (RCT), Outcome 2 Clinical response.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 6 Liposomal daunorubicin versus ABV (RCT)
Outcome: 2 Clinical response
Study or subgroup
Liposomal
daunoru-
bicin ABV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Complete response
Gill 1996 3/116 1/111 100.0 % 2.87 [ 0.30, 27.19 ]
Subtotal (95% CI) 116 111 100.0 % 2.87 [ 0.30, 27.19 ]
Total events: 3 (Liposomal daunorubicin), 1 (ABV)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
2 Partial response
Gill 1996 26/116 30/111 100.0 % 0.83 [ 0.53, 1.31 ]
Subtotal (95% CI) 116 111 100.0 % 0.83 [ 0.53, 1.31 ]
Total events: 26 (Liposomal daunorubicin), 30 (ABV)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
3 Overall response
Gill 1996 29/116 31/111 100.0 % 0.90 [ 0.58, 1.38 ]
Subtotal (95% CI) 116 111 100.0 % 0.90 [ 0.58, 1.38 ]
Total events: 29 (Liposomal daunorubicin), 31 (ABV)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
4 Stable disease
Gill 1996 72/116 64/111 100.0 % 1.08 [ 0.87, 1.33 ]
Subtotal (95% CI) 116 111 100.0 % 1.08 [ 0.87, 1.33 ]
Total events: 72 (Liposomal daunorubicin), 64 (ABV)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Chi2 = 2.19, df = 3 (P = 0.53), I2 =0.0%
0.01 0.1 1 10 100
Favours liposomal daunoru Favours ABV
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Analysis 6.3. Comparison 6 Liposomal daunorubicin versus ABV (RCT), Outcome 3 Adverse events.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 6 Liposomal daunorubicin versus ABV (RCT)
Outcome: 3 Adverse events
Study or subgroup
Liposomal
daunoru-
bicin ABV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gill 1996 113/116 107/111 100.0 % 1.01 [ 0.96, 1.06 ]
Total (95% CI) 116 111 100.0 % 1.01 [ 0.96, 1.06 ]
Total events: 113 (Liposomal daunorubicin), 107 (ABV)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours liposomal daunoru Favours ABV
Analysis 7.1. Comparison 7 Oral etoposide versus ABV (RCT), Outcome 1 Mortality.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 7 Oral etoposide versus ABV (RCT)
Outcome: 1 Mortality
Study or subgroup Oral etoposide ABV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Olweny 2005 84/90 76/88 100.0 % 1.08 [ 0.98, 1.19 ]
Total (95% CI) 90 88 100.0 % 1.08 [ 0.98, 1.19 ]
Total events: 84 (Oral etoposide), 76 (ABV)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours oral etoposide Favours ABV
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Analysis 8.1. Comparison 8 Bleomycin versus ABV (non-RCT), Outcome 1 Mortality.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 8 Bleomycin versus ABV (non-RCT)
Outcome: 1 Mortality
Study or subgroup Bleomycin ABV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hernandez 1997 12/12 11/12 100.0 % 1.09 [ 0.87, 1.36 ]
Total (95% CI) 12 12 100.0 % 1.09 [ 0.87, 1.36 ]
Total events: 12 (Bleomycin), 11 (ABV)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours bleomycin Favours ABV
Analysis 8.2. Comparison 8 Bleomycin versus ABV (non-RCT), Outcome 2 Clinical response.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 8 Bleomycin versus ABV (non-RCT)
Outcome: 2 Clinical response
Study or subgroup Bleomycin ABV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Complete response
Hernandez 1997 0/12 0/12 Not estimable
Subtotal (95% CI) 12 12 Not estimable
Total events: 0 (Bleomycin), 0 (ABV)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Partial response
Hernandez 1997 0/12 4/12 100.0 % 0.11 [ 0.01, 1.86 ]
Subtotal (95% CI) 12 12 100.0 % 0.11 [ 0.01, 1.86 ]
Total events: 0 (Bleomycin), 4 (ABV)
0.01 0.1 1 10 100
Favours bleomycin Favours ABV
(Continued . . . )
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(. . . Continued)
Study or subgroup Bleomycin ABV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
3 Stable disease
Hernandez 1997 7/12 8/12 100.0 % 0.88 [ 0.47, 1.63 ]
Subtotal (95% CI) 12 12 100.0 % 0.88 [ 0.47, 1.63 ]
Total events: 7 (Bleomycin), 8 (ABV)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
4 Progression
Hernandez 1997 5/12 0/12 100.0 % 11.00 [ 0.67, 179.29 ]
Subtotal (95% CI) 12 12 100.0 % 11.00 [ 0.67, 179.29 ]
Total events: 5 (Bleomycin), 0 (ABV)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.092)
Test for subgroup differences: Chi2 = 5.21, df = 2 (P = 0.07), I2 =62%
0.01 0.1 1 10 100
Favours bleomycin Favours ABV
Analysis 8.3. Comparison 8 Bleomycin versus ABV (non-RCT), Outcome 3 Adverse events.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 8 Bleomycin versus ABV (non-RCT)
Outcome: 3 Adverse events
Study or subgroup Bleomycin ABV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hernandez 1997 5/12 0/12 100.0 % 11.00 [ 0.67, 179.29 ]
Total (95% CI) 12 12 100.0 % 11.00 [ 0.67, 179.29 ]
Total events: 5 (Bleomycin), 0 (ABV)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.092)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours bleomycin Favours ABV
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Analysis 9.1. Comparison 9 Liposomal doxorubicin versus conservative management (non-RCT), Outcome
1 Mortality.
Review: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults
Comparison: 9 Liposomal doxorubicin versus conservative management (non-RCT)
Outcome: 1 Mortality
Study or subgroup
Liposomal
doxoru-
bicin
Conservative
management Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gru¨naug 1998 18/20 9/9 100.0 % 0.93 [ 0.75, 1.15 ]
Total (95% CI) 20 9 100.0 % 0.93 [ 0.75, 1.15 ]
Total events: 18 (Liposomal doxorubicin), 9 (Conservative management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours liposomal doxorubicin Favours conservative mana
A D D I T I O N A L T A B L E S
Table 1. Table 1. Cochrane CENTRAL search strategy
ID Search
#1 MeSH descriptor: [Sarcoma, Kaposi] explode all trees
#2 kaposi or karposi or KS
#3 MeSH descriptor: [Herpesvirus 8, Human] explode all trees
#4 hhv-8 or hhv8 or KSHV or “ human herpes virus 8” or “human herpesvirus 8”
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [HIV Infections] explode all trees
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Table 1. Table 1. Cochrane CENTRAL search strategy (Continued)
#7 MeSH descriptor: [HIV] explode all trees
#8 hiv or hiv-1* or hiv-2* or hiv1 or hiv2 or HIV INFECT* or HUMAN IMMUNODEFICIENCY VIRUS or HUMAN
IMMUNEDEFICIENCY VIRUS or HUMAN IMMUNE-DEFICIENCY VIRUS or HUMAN IMMUNO-DEFICIENCY
VIRUS or HUMAN IMMUN* DEFICIENCY VIRUS or ACQUIRED IMMUNODEFICIENCY SYNDROME or AC-
QUIRED IMMUNEDEFICIENCY SYNDROME or ACQUIRED IMMUNO-DEFICIENCY SYNDROME or AC-
QUIRED IMMUNE-DEFICIENCY SYNDROME or ACQUIRED IMMUN* DEFICIENCY SYNDROME
#9 MeSH descriptor: [Lymphoma, AIDS-Related] this term only
#10 MeSH descriptor: [Sexually Transmitted Diseases, Viral] this term only
#11 #6 or #7 or #8 or #9 or #10
#12 #5 and #11 from 1980 to 2012, in Trials (Word variations have been searched)
Table 2. Table 2. PubMed search strategy
Search Query
#12 Search ((#1 AND #2 AND #10)) AND (“1980/01/01”[Date - Publication] : “2012/11/0”[Date - Publication])
#11 Search (#1 AND #2 AND #10)
#10 Search (#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#9 Search ((observational[tiab] AND (study[tiab] OR studies[tiab]))
#8 Search (evaluation studies as topic[mh:noexp] OR (evaluation[tiab] AND (study[tiab] OR studies[tiab]))
#7 Search (cross-sectional studies[mh] OR cross section*[tiab])
#6 Search (case control studies[mh] OR case control[tiab])
#5 Search ((follow up[tiab] OR prospective[tiab] OR longitudinal[tiab] OR retrospective[tiab]) AND (study[tiab] OR stud-
ies[tiab]))
#4 Search (cohort studies[mh] OR cohort[tiab] OR cohorts[tiab])
#3 Search (randomised controlled trial [pt] OR controlled clinical trial [pt] OR randomised [tiab] OR placebo [tiab] OR drug
therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])
#2 Search sarcoma, kaposi[mh] OR kaposi*[tiab] OR karposi*[tiab] OR KS[tiab] OR herpesvirus 8, human[mh] OR human
herpes virus 8[tiab] OR human herpesvirus 8[tiab] OR hhv-8[tiab] OR hhv8[tiab] OR KSHV[tiab]
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Table 2. Table 2. PubMed search strategy (Continued)
#1 Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab] OR
hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immunedeficiency virus[tiab] OR
human immuno-deficiency virus[tiab] OR human immune-deficiency virus[tiab] OR ((human immun*[tiab]) AND (defi-
ciency virus[tiab]))OR acquired immunodeficiency syndrome[tiab]OR acquired immunedeficiency syndrome[tiab]OR ac-
quired immuno-deficiency syndrome[tiab] OR acquired immune-deficiency syndrome[tiab] OR ((acquired immun*[tiab])
AND (deficiency syndrome[tiab])) OR “sexually transmitted diseases, Viral”[MeSH:NoExp])
Table 3. Table 3. EMBASE search strategy
No. Query
#16 #1 AND #13 AND #14 AND [embase]/lim AND [1-1-1980]/sd NOT [26-11-2012]/sd
#15 #1 AND #13 AND #14
#14 ’kaposi sarcoma’/exp OR ’kaposi sarcoma’ OR ’human herpesvirus 8’/exp OR ’human herpesvirus 8’ OR kaposi*:ab,ti OR
karposi*:ab,ti OR ks:ab,ti OR ’human herpes virus 8’:ab,ti OR ’hhv-8’:ab,ti OR hhv8:ab,ti OR kshv:ab,ti
#13 #7 OR #8 OR #9 OR #10 OR #11 OR #12
#12 ’observational study’/exp OR (observational NEXT/1 (study OR studies)):ab,ti
#11 ’evaluation’/exp OR (evaluation NEXT/1 (study OR studies)):ab,ti
#10 ’cross-sectional study’/exp OR (cross NEXT/1 section*):ab,ti
#9 ’case control study’/exp OR ’case control’:ab,ti
#8 ’cohort analysis’/exp OR ’cohort analysis’ OR ’longitudinal study’/exp OR ’longitudinal study’ OR ’prospective study’/exp
OR ’prospective study’ OR ’follow up’/exp OR ’follow up’ OR cohort*:ab,ti OR ’longitudinal studies’:ab,ti OR ’prospective
studies’:ab,ti
#7 #2 NOT #6
#6 #3 NOT #5
#5 #3 AND #4
#4 ’human’/de
#3 ’animal’/de OR ’nonhuman’/de OR ’animal experiment’/de
#2 ’randomised controlled trial’/de OR ’randomised controlled trial (topic)’/exp OR random*:ab,ti OR trial:ti OR allocat*:ab,ti
OR placebo*:ab,ti OR ’crossover procedure’/de OR ’double-blind procedure’/de OR ’single-blind procedure’/de OR (doubl*
NEAR/3 blind*):ab,ti OR (singl* NEAR/3 blind*):ab,ti OR crossover*:ab,ti OR cross+over*:ab,ti OR (cross NEXT/1 over*)
:ab,ti
69Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Table 3. EMBASE search strategy (Continued)
#1 ’human immunodeficiency virus infection’/exp OR ’human immunodeficiency virus’/exp OR ’human immunodefi-
ciency virus’:ab,ti OR ’human immuno+deficiency virus’:ab,ti OR ’human immunedeficiency virus’:ab,ti OR ’human im-
mune+deficiency virus’:ab,ti OR hiv:ab,ti OR ’hiv-1’:ab,ti OR ’hiv-2’:ab,ti OR ’acquired immunodeficiency syndrome’:ab,
ti OR ’acquired immuno+deficiency syndrome’:ab,ti OR ’acquired immunedeficiency syndrome’:ab,ti OR ’acquired im-
mune+deficiency syndrome’:ab,ti
A P P E N D I C E S
Appendix 1. Newcastle-Ottawa Quality Assessment Scale
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A
maximum of two stars can be given for Comparability.
Selection
1) Representativeness of the exposed cohort
a) truly representative of the average HIV-infected adults with severe KS in the community *
b) somewhat representative of the average severe KS in the community *
c) selected group of users
d) no description of the derivation of the cohort
2) Selection of the non-exposed cohort
a) drawn from the same community as the exposed cohort *
b) drawn from a different source
c) no description of the derivation of the non-exposed cohort
3) Ascertainment of exposure
a) secure record (e.g. surgical records) *
b) structured interview *
c) written self report
d) no description
4) Demonstration that outcome of interest was not present at start of study
a) yes *
b) no
Comparability
1) Comparability of cohorts on the basis of the design or analysis
a) study controls for age, sex and other primary factor *
b) study controls for any additional factor *
Outcome
1) Assessment of outcome
a) independent blind assessment *
b) record linkage *
c) self report
d) no description
2) Was follow-up long enough for outcomes to occur?
a) yes (median duration of follow-up > 6 months) *
b) no
3) Adequacy of follow-up of cohorts
a) complete follow-up - all subjects accounted for *
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b) subjects lost to follow-up unlikely to introduce bias - small number lost to follow-up (≤ 20%), or description provided of those lost
*
c) follow-up rate < 80% and no description of those lost
d) no statement
NOS - CODING MANUAL FOR COHORT STUDIES
SELECTION
1) Representativeness of the exposed cohort (NB exposure = intervention)
Item is assessing the representativeness of exposed individuals in the community, not the representativeness of the study sample from
some general population. For example, subjects derived from groups likely to contain exposed people are likely to be representative of
exposed individuals, while they are not representative of all people the community.
Allocation of points as per rating sheet.
2) Selection of the non-exposed cohort
Allocation of points as per rating sheet.
3) Ascertainment of exposure
Allocation of points as per rating sheet.
4) Demonstration that outcome of interest was not present at start of study
In the case of mortality studies, outcome of interest is still the presence of a disease/incident, rather than death. That is to say that a
statement of no history of disease or incident earns a point.
COMPARABILITY
1) Comparability of cohorts on the basis of the design or analysis
Either exposed or non-exposed individuals must be matched in the design and/or confounders must be adjusted for in the analysis.
Statements of no differences between groups or that differences were not statistically significant are not sufficient for establishing
comparability. Note: If the relative risk for the exposure of interest is adjusted for the confounders listed, then the groups will be
considered to be comparable on each variable used in the adjustment.
A maximum of 2 points can be allotted in this category.
OUTCOME
2) Assessment of outcome
For some outcomes, reference to the medical record is sufficient to satisfy the requirement for confirmation. This may not be adequate
for other outcomes where reference to specific tests or measures would be required.
a) Independent or blind assessment stated in the paper, or confirmation of the outcome by reference to secure records (health records,
etc.)
b) Record linkage (e.g. identified through ICD codes on database records)
c) Self report (i.e. no reference to original health records or documented source to confirm the outcome)
d) No description
3) Was follow-up long enough for outcomes to occur?
An acceptable length of time should be decided before quality assessment begins.
4) Adequacy of follow-up of cohorts
This item assesses the follow-up of the exposed and non-exposed cohorts to ensure that losses are not related to either the exposure or
the outcome.
Allocation of points as per rating sheet.
For some outcomes, reference to the medical record is sufficient to satisfy the requirement for confirmation. This may not be adequate
for other outcomes where reference to specific tests or measures would be required.
a) Independent or blind assessment stated in the paper, or confirmation of the outcome by reference to secure records (health records,
etc.)
b) Record linkage (e.g. identified through ICD codes on database records)
c) Self report (i.e. no reference to original health records or documented source to confirm the outcome)
d) No description
3) Was follow-up long enough for outcomes to occur?
An acceptable length of time should be decided before quality assessment begins.
4) Adequacy of follow-up of cohorts
This item assesses the follow-up of the exposed and non-exposed cohorts to ensure that losses are not related to either the exposure or
the outcome.
Allocation of points as per rating sheet.
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Appendix 2. Newcastle-Ottawa Quality Assessment Scale for Included Cohort Studies
Study ID Selection (maximum of 4 stars) Comparability (maximum of 2 stars) Outcome (maximum of 3 stars)
Bower 2009 *** * ***
Grunaug 1998 **** ** ***
Hernandez 1997 *** * ***
Selection
1) Representativeness of the exposed cohort
a) truly representative of the average HIV infected adults with severe KS in the community * , b) somewhat representative of the average
severe KS in the community *, c) selected group of users , d) no description of the derivation of the cohort
2) Selection of the non-exposed cohort
a) drawn from the same community as the exposed cohort *, b) drawn from a different source, c) no description of the derivation of
the non-exposed cohort
3) Ascertainment of exposure
a) secure record (eg surgical records) *, b) structured interview *, c) written self report, d) no description
4) Demonstration that outcome of interest was not present at start of study
a) yes *, b) no
Comparability
1) Comparability of cohorts on the basis of the design or analysis
a) study controls for age, sex and other primary factor *, b) study controls for any additional factor *
Outcome
1) Assessment of outcome
a) independent blind assessment * , b) record linkage *, c) self report, d) no description
2) Was follow-up long enough for outcomes to occur
a) yes (median duration of follow-up > 6 months) * , b) no
3) Adequacy of follow up of cohorts
a) complete follow up - all subjects accounted for * , b) subjects lost to follow up unlikely to introduce bias - small number lost ( ≤ 20
%) to follow up, or description provided of those lost *, c) follow up rate < 80% and no description of those lost, d) no statement
WH A T ’ S N E W
Last assessed as up-to-date: 13 August 2014.
Date Event Description
4 July 2014 New citation required and conclusions have changed New searches. Review updated and conclusions changed.
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H I S T O R Y
Protocol first published: Issue 2, 2001
Review first published: Issue 3, 2003
Date Event Description
10 November 2008 Amended Converted to new review format.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This is an update of a previous Cochrane systematic review. In this update, we have included data only for participants with severe
Kaposi’s sarcoma. Data for participants with mild or moderate Kaposi’s sarcoma will be presented in a separate review (Freeman E. et
al, “Treatment for mild and moderate Kaposi’s sarcoma in ART-naive HIV-infected individuals,” Cochrane review in progress).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Antiretroviral Therapy, Highly Active; Antineoplastic Agents [∗therapeutic use]; Bleomycin [administration & dosage]; Doxorubicin
[administration & dosage]; Drug Therapy, Combination; Etoposide [administration & dosage]; HIV Infections [∗complications;
drug therapy]; Liposomes; Observational Studies as Topic; Randomized Controlled Trials as Topic; Sarcoma, Kaposi [∗drug therapy;
virology]; Skin Neoplasms [∗drug therapy; virology]; Tretinoin [therapeutic use]; Vincristine [administration & dosage]
MeSH check words
Humans
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